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Respir Med 1993; 87 (suppl B): 37-39Abstract
Nocturnal symptoms are common in asthma, even when patients are regularly seen
at an outpatient clinic. Inflammation is generally accepted as a general feature of
asthma and the severity of this basic inflammatory process can be increased by
exogenous triggers such as exposure to allergens and non-allergic stimuli.
Superimposed endogenous circadian rhythms may play a more important and
intricate role in the circadian modulation of the inflammatory process by changing
the number of cells, their release of mediators and/or the susceptibility of airway
smooth muscle and vasculature. For instance, an increase in vagal tone may induce
nocturnal bronchoconstriction which is further enhanced by falling catecholamine
levels. Together, the reduced nocturnal catecholamine levels and the diminished
bronchodilating capacity of the NANC system and the low cortisol levels oppose
possible protection against inflammatory processes leading to nocturnal airflow
obstruction.
Introduction
Nocturnal symptoms of dyspnoea and wheezing are common in asthmatic patients
and are thought to be related to the severity of the disease (1). Both in healthy
subjects and asthmatic patients a circadian variation in airway diameter exists, with
best lung function values during the day and worst values at night. In healthy
subjects differences between daytime and nighttime values are small, in asthmatic
patients they may be large with the consequence of nocturnal airflow limitation and
symptoms such as cough, wheeze, dyspnoea and waking up.
Although nocturnal complaints of asthma have been recognized for a long time,
little is known about its epidemiology. The mechanisms that contribute to the
amplified 24 hours swings in pulmonary function are not yet fully clear but the
concept is growing. In this article we will focus on both epidemiology and
pathophysiology and try to come to a concept of mechanisms that play a role in
nocturnal asthma.
Epidemiology
Throughout history the occurrence of nocturnal complaints of asthma have been
reported (2).
In 1973 the first epidemiological study on the prevalence of nocturnal asthma
appeared and was repeated in 1988. Turner-Warwick showed in 1988 that 39% of a
non-hospital-based population in the United Kingdom woke up every night, 64%
woke up at least 3 nights per week and 74% woke up at least 1 night per week (3).
41.1 Epidemiology and mechanisms of nocturnal asthma
These data were comparable to those of the study 15 yrs earlier, and the author
concluded that not much had changed despite the introduction of inhaled
corticosteroids.
In 1991 we studied the epidemiology of nocturnal complaints and early morning
dyspnoea in 796 asthmatic children from our own outpatient clinic. The
questionnaire referred to the last 3 weeks before a regular control visit. Forty seven
percent reported nocturnal complaints or early morning dyspnoea. Only 6%
reported to have complaints every night. In our population as well as in the study
population from the United Kingdom about half of the patients used inhaled
corticosteroids, drugs known to reduce the 24 hour amplitude of the lung function.
The difference in results between the two studies may be explained by differences
in age of the study populations and probably differences in frequency of medical
control, since the population studied by Turner-Warwick was only defined as
patients for whom an inhaled bronchodilator was prescribed by a general physician.
Despite differences in outcome of the two studies, we have to conclude that
nocturnal symptoms of asthma are still common in the nineties even in a regularly
controlled asthmatic population.
Mechanisms
Both exogenous triggers, and probably more important, circadian variations in
endogenous mechanisms, such as bronchial responsiveness, the autonomic central
nervous system and cortisol secretion, modulate the inflammatory processes in the
airways underlying the asthmatic expression. This may ultimately result in variation
of the airway diameter over 24 hours.
BRONCHIAL RESPONSIVENESS
The increase in airflow obstruction during the night was thought to be a
consequence of the increase in bronchial responsiveness that was observed at the
same time (4). However, in asthmatic children we found that the circadian variation
in bronchial responsiveness can be independent of the degree of airflow obstruction
(5) as confirmed by Bonnet et al. (6). This indicates that an increase in bronchial
responsiveness overnight in itself is not responsible for nocturnal airflow
obstruction and that other factors are involved.
CORTISOL
Corticosteroids are well-known for their beneficial effect in restoring pulmonary
function in severe asthma attacks with a latency of several hours. The circadian
variation in serum cortisol shows trough levels at 01.00 h and peak levels about
08.00 h. Postma et al. (7) observed levels of serum cortisol in patients with chronic
obstructive pulmonary disease (COPD) comparable to those in the matched healthy
5controls. Together with the observation that infusion of cortisol did not prevent the
nocturnal fall in pulmonary function in five out of six patients (8) has led to the
believe that the fall in cortisol during the early night is not in itself responsible for
the decrease in airway diameter at 04.00 h.
THE AUTONOMIC NERVOUS SYSTEM
The circadian variation in airway diameter is known to be under control of various
components of the autonomic nervous system such as the parasympathetic system,
ß-adrenergic sympathetic system and the non-adrenergic non-cholinergic (NANC)
system.
The parasympathetic system
Increased parasympathetic tone causes a decrease in the airway diameter. In adult
patients with asthma and in patients with COPD an increase in parasympathetic
activity was observed during the night (9,10). We were unable to confirm this
finding in children with nocturnal asthma (11). Moreover, after heart-lung trans-
plantation, when vagal innervation is lost, a circadian variation in airway diameter
is still present (12). These observations indicate that parasympathetic activity
contributes, but does not fully explain nocturnal airflow obstruction.
The ß-adrenergic system
The ß-adrenergic system is of importance for airway dilatation and consists of
circulating catecholamines and ß-receptors on cell membranes of inflammatory
cells, cholinergic ganglia and airway smooth muscle. Circulating catecholamines
such as adrenaline and noradrenaline show a circadian variation with lowest levels
at 04.00 h coinciding with the nocturnal increase in airflow obstruction. ß2-receptor
density on peripheral blood cells is also lowest during the night. These observations
suggest that the diminished bronchodilating capacity during the night is responsible
for the nocturnal increase in airflow obstruction. However, correction of the
nocturnal dip in serum adrenaline by infusion of adrenaline did not prevent the fall
in pulmonary function (10). Moreover, we did not observe differences in adrenaline
and noradrenaline urinary excretion between asthmatic children with and without
increased nocturnal airflow obstruction and their healthy controls (13). This
indicates that a fall in circulating catecholamines during the night does not have a
direct action on bronchial smooth muscle tone. This fall will provide a smaller
protective effect on for instance mast cells, thereby inducing histamine and other
mediator release (13). Furthermore, increasing vagal tone can be opposed by inhi-
bition of cholinergic neurotransmission at the level of parasympathetic ganglia and
may permit an increase in microvascular leakage, ultimately leading to an increase
in airflow obstruction.
The non-adrenergic non-cholinergic system
61.1 Epidemiology and mechanisms of nocturnal asthma
A circadian variation in NANC neurotransmission has been found as well: a
decreased bronchodilator response upon stimulation with capsaicin was found at
04.00 h as compared to 16.00 h in healthy subjects and in asthmatics (14). This
decreased bronchodilator response in the morning may result from central modula-
tion of the stimulus or from inhibition of the efferent activity. The authors
concluded that nocturnal airflow obstruction in asthmatic subjects may be partly
caused by a decreased NANC bronchodilatation.
Concept of mechanisms in nocturnal asthma
It is generally accepted that a specific inflammatory process underlies the
pathogenesis of asthma. That an inflammatory process may play a role in nocturnal
asthma is supported by the observation that anti-inflammatory drugs such as inha-
led corticosteroids reduce the overnight fall in pulmonary function (15).
Martin et al. (13) showed, at least in some, but certainly not in all patients with
nocturnal asthma an increase in numbers of eosinophils and neutrophils in the
nocturnal bronchoalveolar lavage (BAL) fluid as compared to daytime numbers.
Jarjour et al. (16) did not observe day-night variations in inflammatory cells in the
BAL fluid. Lungbiopsies will probably provide an answer whether an influx and
activation of inflammatory cells in the lungs overnight are responsible for the fall
in pulmonary function.
At this time we hypothesize the inflammatory process to be a general feature in
asthma. The severity of this basic inflammatory process can be increased by exoge-
nous triggers, such as exposure to allergens and non-allergic stimuli. Superimposed
endogenous circadian rhythms may play a more important and intricate role in the
circadian modulation of the inflammatory process by changing number of cells,
their release of mediators and/or the susceptibility of airway smooth muscles and
vasculature. Increased vagal tone may induce nocturnal bronchoconstriction. Falling
catecholamine levels overnight may induce further decrease of the airway diameter.
Together with the reduced nocturnal catecholamine levels, diminished bron-
chodilating capacity of the NANC system and low cortisol levels oppose possible
protection against inflammatory processes, leading to nocturnal airflow obstruction.
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8CHAPTER 1.2
AIMS OF THE THESISIn this thesis several exogenous factors that may influence the severity of nocturnal
airflow limitation in asthmatic children are investigated. Next to the influence of
these exogenous factors we investigated the frequency of nocturnal symptoms on
our pediatric asthma outpatient clinic.
In Chapter 1.1 a concept of possible mechanisms and interactions between
endogenous and exogenous factors that may underly nocturnal airflow limitation is
discussed.
In Chapter 2 we investigated the frequency of nocturnal symptoms such as
coughing, wheezing, shortness of breath and dyspnea on awakening in the morning
in our asthmatic outpatient clinic in children with asthma.
In Chapter 3 a study is presented in which we investigated whether house dust
mite exposure levels in houses of asthmatic children are higher than in houses of
healthy controls.
In Chapter 4 a study is presented in which we investigated the wheter exogenous
factors such as environmental tobacco smoke, the presence of pets, and the levels
of house dust mite in houses of asthmatic children with a mono-allergy to house
dust mite contributed to an increased circadian peak expiratory flow amplitude.
In Chapter 5 a study is presented in which we investigated whether the seasonal
variations in house dust mite exposure contributed to an increase in circadian peak
expiratory flow amplitude in asthmatic children with a mono-allergy to house dust
mite.
In Chapter 6 we discussed that mite-specific IgE could not be used as an
alternative for house dust mite exposure in answer to a study in which the authors
suggested that that this could be done.
In Chapter 7 a study is presented in which we investigated in asthmatic children
who were already treated with inhaled corticosteroids whether 16 weeks of
treatment with the long acting ß-adrenergic drug salmeterol leads to a sustained
bronchodilator effect and decreased bronchial responsiveness during the day and
night. Furthermore, we assessed whether cessation of salmeterol after 4 months,
when added to a regime with inhaled corticosteroids, leads to a rebound increase in
bronchial responsiveness.
In Chapter 8 a study is presented in which we investigated daytime and nighttime
inflammatory parameters in healthy children and in asthmatic children treated with
inhaled corticosteroids. Moreover, we assessed whether differences in inflammation
101.2 Aims of the thesis
between healthy and asthmatic children are associated with lung function
parameters and whether long-term treatment with salmeterol influenced
inflammatory parameters.
11CHAPTER 2
FREQUENCY OF NOCTURNAL SYMPTOMS
IN ASTHMATIC CHILDREN ATTENDING
A HOSPITAL OUTPATIENT CLINIC
Gerda G Meijer
1, Dirkje S Postma
2, Johan B Wempe
2, Jorrit Gerritsen
1,
Klaas Knol
1, Wim MC van Aalderen
1
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Eur Respir J 1995; 8: 2076-2080Abstract
Since nocturnal symptoms indicate more severe asthma we investigated the
frequency in a hospital-based population of asthmatic children. Recognition of
these symptoms offer the possibility to introduce appropriate treatment. We studied
796 consecutive children with asthma (mean age (SD) age 9 (4) yrs) attending a
hospital clinic, to determine whether these nocturnal symptoms predicted that
daytime activities would be affected, and also the patients’ perception of disease
severity. At the end of a regular outpatient clinic visit, the answers to seven
different questions concerning nocturnal symptoms in the previous 3 weeks were
recorded. The forced expiratory volume in one second (FEV1) was ³ 90% predicted
in 98% of the population that was able to perform lung function measurements
(72% of the total population). In 38% of the patients with nocturnal symptoms,
these symptoms were reported spontaneously. When asked for, nocturnal symptoms
were reported by 47% of the children; 6% every night and 34% at least once a
week. Cough was the most frequently reported symptom (31%). Children with
nocturnal symptoms had a lower FEV1, scored their perception of asthma as more
severe, and had their daytime activities affected more than those without nocturnal
symptoms. Doctors should specifically ask about nocturnal symptoms, as not all
patients with nocturnal symptoms report them spontaneously and they predict more
severe disease.
Introduction
A circadian variation in peak flow rate exists both in healthy subjects and
asthmatics, with best lung function values during the day and worst values during
the night (1-3). The difference is due to a change in airway size at night (4).
Nocturnal dyspnoea, cough, wheeze as well as dyspnoea on wakening in the
morning are common symptoms in asthmatic patients (5). Dyspnoea on wakening
in the morning is an indicator of the nocturnal fall in lung function at night. In
children, it may cause patients and their parents to wake at night, and may lead to
poorer educational and cognitive performance (6,7).
Nocturnal symptoms of asthma have been recognized for a long time (8). Since
they indicates severe asthma, these symptoms would be expected to be common in
a hospital-based populations of asthmatics. We investigated the frequency and types
of nocturnal symptoms in children with stable asthma, who regularly visited our
outpatient clinic, and also their effect on perception of asthma severity and daytime
activity.
142. Frequency of nocturnal symptoms
Patients and methods
Study Design
Children who were regular clinic attenders participated in our study between
September 1990 and September 1991. All answered seven different questions
concerning nocturnal symptoms in the previous 3 weeks. Questions were answered
by the child or by the parents of younger children at the end of the outpatient visit
after the usual history, physical examination and lung function tests had been
completed.
Patients
All children were previously diagnosed as having asthma based on a history of
recurrent episodes of wheeze, dyspnoea and coughing in response to allergens or
non-allergic stimuli. History was taken according to the Dutch version of the
standardized questionnaire of the British Medical Research Council (MRC
European Coal and Steel Community (ECCS) questionnaire) (9).
Patients with viral infections or asthma exacerbations during the outpatient visit
were excluded from the study.
Questionnaire
The questionnaire concerning nocturnal symptoms in the previous 3 weeks was
administered by one of the 4 authors (GGM, JG, KK, WMCvA). Spontaneously
reported nocturnal symptoms were noted. For this study, questions concerning
nocturnal asthma were, deliberately, not asked by the physician before the
questionnaire. All medication was recorded.
The following questions were asked:
1. Do you (does your child) wake up at night due to a) dyspnoea, b) cough, c)
wheeze, d) do you (does your child) suffer from dyspnoea on wakening in
the morning? Possible answers were yes or no? [Type of symptoms].
2. How often per week do you (does your child) suffer from symptoms
mentioned under 1? [Frequency].
3. Do you consider the severity of your asthma (the asthma of your child) as
mild, moderate, severe or very severe [Severity].
4. If there are nocturnal symptoms, do they generally influence activities during
the next day?
The terms between square brackets are used to indicate the different questions in
Tables 1 and 2.
The study protocol was approved by the University Hospital Ethical Committee.
Lung Function Measurements
In children of 6 yrs and older (n = 576), 72% of the population under study, forced
expiratory volume in one second (FEV1) was measured with a water-sealed
15spirometer (Lode bv, Groningen, the Netherlands). The best of three FEV1 efforts
was used for statistical analysis. Normal values from Zapletal et al. were used (10).
Statistical Analysis
Statistical analysis was performed using SPSS/PC, version 4.0 (SPSS Inc., Chicago,
USA). Values for age and FEV1 (expressed as percentage of the predicted value
[%pred]) had a normal distribution (Kolmogorov-Smirnov test), and are presented
as means and standard deviations (SD). The group difference for FEV1 has been
analyzed with a Student’s t test. Comparison between children with one or more
affirmative answer(s) to the questions on nocturnal symptoms and those children
who answered these questions negatively, have been analyzed by Chi-square test.
For the relation of FEV1 with the subjectively estimated severity grades, analysis of
variance (ANOVA) was used. The analysis of the dependent variables for the
estimation of subjective perception of the severity of the disease have been
assessed with logistic regression and are presented as Odds ratio (OR) and 95%
confidence interval (95% CI). A difference of 5% was considered as significant.
Results
Patients
Patients (n = 796, 512 boys (64%) and 284 girls (36%); mean (SD) age 9 (4) yrs)
were labelled nocturnal asthma positive (NA+) when one or more of the questions
on nocturnal symptoms were answered affirmatively, and nocturnal asthma negative
(NA-) when these questions were answered negatively.
FEV1
Ninety eight percent of the 576 children who performed lung function
measurements had a FEV1 ³ 90 % pred. Mean FEV1 values were significantly
lower (p < 0.01) in the NA+ group than in the NA- group (97.5 ± 6.5% and 98.8 ±
2.9%, respectively).
Type of Symptoms and Frequency
Almost half of the children (375 = 47%) had nocturnal symptoms. Cough was the
most frequently reported symptom (31%), although it often occurred in
combination with other symptoms. Dyspnoea at night (25%), dyspnoea on
wakening in the morning (25%) and wheeze (18%) were less frequently reported.
Nocturnal symptoms were present on every night in 6% of the children, and 34%
reported having nocturnal symptoms at least once a week (Table 3). The NA+
group used significantly (p < 0.01) more maintenance medication (inhaled
corticosteroids, cromolyn sodium, and ketotifen) than the NA- group (Table 4).
162. Frequency of nocturnal symptoms
Subjective Perception of Severity of Asthma
Subjective perception of asthma was considered to be mild or moderate in 88% of
the children, and severe or very severe by 11% (Table 1). Subjective perception of
severity by patients in the NA+ group was significantly different from the NA-
group (p < 0.01); more children in the NA+ group regarded their asthma as severe
or very severe. Mean FEV1 values did not vary between the four groups with
different subjective perception of severity grades (mild, n = 317: 98.5 ± 2.9%;
moderate, n = 212: 97.9 ± 6.9%; severe, n = 44: 97.7 ± 2.7%; very severe,n=3 :
99.4 ± 1.3%; ANOVA p = 0.47).
Daytime activities were influenced by nocturnal symptoms in 33% of the total
population, this was 46% of the NA+ group and 20% of the NA- group (p < 0.01).
The 20% of the NA- group were those who reported that before the 3 weeks of the
questionnaire daytime activities were influenced by nocturnal symptoms.
Nocturnal symptoms were spontaneously reported in 25% of the total population,
this was 38% of the NA+ group and 12% of the NA- group (p < 0.01). The 12%
of the NA- group were those who spontaneously reported that their nocturnal
symptoms that were apparent before the 3 weeks of the questionnaire had
disappeared.
Table 2 shows the distribution of type and frequency of nocturnal symptoms by
perceived severity of asthma in the population. The difference between mild versus
moderate, severe and very severe was discriminated by nocturnal wheezing (OR:
2.45; 95% CI: 1.54 - 3.94), dyspnoea on wakening in the morning (OR: 1.90; 95%
CI: 1.26 - 2.86) and the frequency of nocturnal symptoms (OR: 1.35; 95% CI: 1.20
- 1.52). Moderate versus severe and very severe disease were discriminated by
dyspnoea at night (OR: 2.31; 95% CI: 1.36 - 3.94) and dyspnoea on wakening in
the morning (OR: 1.90; 95% CI: 1.12 - 3.22).
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82. Frequency of nocturnal symptoms
TABLE 2 Subjective perception of severity of asthma by type and frequency of nocturnal
symptoms
Mild Moderate Severe Very severe
(n=401) (n=304) (n=79) (n=6)
Type of symptoms
Dyspnoea at night 58 93 44 4
Cough 84 111 40 4
Wheeze 31 74 33 4
Dyspnoea on wakening 53 98 44 3
in the morning
Frequency
0 or < 1 /week 329 164 26 2
1x / week 27 31 12 -
2x / week 14 38 10 1
3x / week 10 26 8 1
4-6x / week 10 18 12 1
Every night 11 27 11 1
19TABLE 3 Frequency of nocturnal symptoms in 796 children with stable asthma who
were regular clinic attenders
Nocturnal symptoms n %
None 421 53
Less than once a week 102 13
Once a week 71 9
Twice a week 65 8
Three times a week 46 6
Four - six times a week 41 5
Every night 50 6
202. Frequency of nocturnal symptoms
TABLE 4 Patient medication
Total NA+ NA-
n = 796 n = 375 n = 421
n% n% n%
None 88
11 17 5 71 17
Maintenance medication *
None 123 16 39 10 84 21
Corticosteroids # 398 50 190 51 208 49
Cromolyn sodium # 190 24 100 27 90 21
Ketotifen 85 10 46 12 39 9
Bronchodilators
Salbutamol #
Regular 159 20 98 26 61 15
On demand 423 53 222 59 201 48
Ipratropium bromide #
Regular 24 3 18 5 6 1
On demand 1 0 1 0 - -
Theophylline 22 3 18 5 4 1
Total: all subjects; NA+: subjects with nocturnal symptoms; NA-: subjects without noc-
turnal symptoms. #: inhaled. *: NA+ group used more (p < 0.01) maintenance medication
than the NA- group.Discussion
Although nocturnal symptoms are considered to be a common phenomenon in asthmatic
patients, nothing is known about their frequency in a hospital-based population. In a cross-
sectional survey in our paediatric population, approximately half of the patients suffered
from nocturnal symptoms of asthma during the 3 weeks before their regular outpatient
clinic visit. Nevertheless, 89% of the patients regarded their asthma to be moderate or
mild. Patients with nocturnal symptoms of asthma had a significantly lower FEV1, reported
often that their nocturnal symptoms influenced daytime activities, and assessed their
asthma as severe significantly more often than those without nocturnal symptoms. Only
38% of the parents and patients with nocturnal symptoms reported it spontaneously.
Results of the routine outpatient FEV1 values were a poor predictor of nocturnal
symptoms. Cough was the highest reported symptom.
Connolly (11) estimated that one third of adult patients with asthma attending a clinic
suffered from nocturnal symptoms. In 1988 Turner-Warwick (5) showed that 39% of the
patients in a non-hospital-based population woke every night, 64% woke at least 3 nights
per week and 74% woke at least 1 night per week. These percentages were very close to
those of a similar study by the same author fifteen years earlier. It was therefore
concluded that the frequency of nocturnal symptoms of asthma had not diminished despite
the introduction of newer drugs, such as inhaled corticosteroids.
Our study shows a lower frequency of nocturnal symptoms than reported in the United
Kingdom (5), a difference which is likely to be due to selection of patients. We studied a
hospital-based population of asthmatic children, and the use of medication was not an
inclusion criteria. Turner-Warwick (5) studied patients of no specified age to whom a
general physician had prescribed or represcribed an aerosol bronchodilator. Differences in
asthma management may be another factor. Our asthmatic children visit our outpatient
clinic at least once every 6 months, where the clinical history is recorded, and a physical
examination and spirometry are performed.
Medication use was not different between our population and the population studied by
Turner-Warwick (5). Forty eight percent of the latter study population also used inhaled
corticosteroids, while 50% of our children used this type of medication. Despite the
differences in outcome of the two studies, we conclude that nocturnal symptoms of asthma
are still common, even an asthmatic population regularly attending an outpatient clinic.
Foo and Sly (12) investigated baseline pulmonary function with symptom scores and home
monitoring of peak expiratory flow (PEF) variability in 100 clinically stable asthmatic
children from their outpatient clinic. They found that one third had an abnormal FEV1.W e
found that the majority (98%) of our investigated population had FEV1 values within the
normal range (FEV1 ³ 90% pred). Nevertheless we observed a high frequency of nocturnal
symptoms indicating that the disease is not stable.
Cough was the most frequently reported symptom. Falconer et al. (13) investigated the
correlation between subjective reports of nocturnal symptoms and objective measurements
of PEF recordings and voice activated tape recordings of coughing. They found a poor
correlation between subjective and objective assessment of nocturnal symptoms. Their
observations indicate that our results, based on a questionnaire, may underestimate the real
frequency of nocturnal airway obstruction or cough. However, waking up will probably
have a greater impact on daytime activities than the frequency of recorded coughing sounds.
Dyspnoea on wakening in the morning is a result of the nocturnal fall in lung function. In
an earlier study, we observed that the 8:00 a.m. PEF value correlates well with the 4:002. Frequency of nocturnal symptoms
a.m. value in a group of asthmatic children with increased airway obstruction overnight
(3).
In the current study we labelled 375 (47%) of the population as having nocturnal
symptoms. If we had not asked about dyspnoea on wakening in the morning, 314 (39%)
would have been labelled as having nocturnal symptoms. We would than have missed
about 8% who slept through their nocturnal airway obstruction.
A surprising observation in our study was that nocturnal symptoms were only
spontaneously reported in 38% of those experiencing them. It may be assumed that
children and/or parents are accustomed to nocturnal symptoms and consider them as a
normal feature. As nocturnal asthma is a sign of instability of asthma and associated with
a higher rate of exacerbations (4), our findings have important implications for clinical
practice. As stressed earlier by Henry et al. (14), physicians should specifically ask for
nocturnal symptoms, since these are often not spontaneously reported. Since asthma has
different presentations and symptoms may differ with age group, we emphasize that all
four symptoms should be asked about. Although we did observe significantly lower FEV1
values in the group with nocturnal symptoms than in the group without nocturnal
symptoms, the observed difference is small and mean FEV1 values of both groups were in
the normal range.
Our study indicates that routine outpatient clinic spirometry is a poor predictor for
nocturnal symptoms. A more objective assessment of nocturnal airway obstruction is the
measurement of PEF values on wakening in the morning (3,14). This may help both
parents and physicians to assess the severity of nocturnal airway changes. Moreover, it
provides an indication of the severity of the disease and offers the possibility to introduce
appropriate treatment.
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Aim - To determine whether house dust mite (HDM) exposure in living rooms and
bedrooms is higher in asthmatic children than in those of age and sex matched -
healthy children, living in the same area. Methods - Types of floor-coverings were
recorded and dust samples were collected by vacuum cleaning the total area of
living rooms and bedrooms; Der p I and Der p II per gram of fine dust
concentrations were assessed. Twenty-five asthmatic children (RAST HDM ³ class
3, age 6-12 yrs) and 25 healthy children participated in the study. Results - The
frequency of cleaning and prevalence of smooth floor-coverings in bedrooms of
asthmatic children were significantly higher. There were no differences in living
rooms in this respect. The amount of fine dust/m
2 floor space was significantly
lower in bedrooms of asthmatic children. Concentrations of HDM were low and no
differences in Der p I and Der p II levels were observed between the two groups
(asthmatic children: Der p I living room: 1.1 (0.04 - 59.4 µg/g), bedroom: 0.5
(below detection - 19.3 µg/g); non-asthmatic children: Der p I living room: 1.4
(below detection - 27.5 µg/g), bedroom: 0.9 (below detection - 68.8 µg/g). Smooth
floor-coverings contained significantly less fine dust, Der p I, and Der p II than
carpeted floors. Conclusions - Low HDM concentrations are a general finding in
Dutch dwellings in the present generation of children. We observed a higher
cleaning frequency, and more smooth floor-coverings in bedrooms of asthmatic
children than of healthy children, yet HDM concentrations were not significantly
different. The latter can be explained by the observation that only 40% of the
asthmatic children had smooth floor-coverings in their bedrooms. Smooth floor-
coverings contain less fine dust and lower levels of Der p I and Der p II than
carpeted floors.
Introduction
House dust mites (HDM) are the most important allergens for inducing asthmatic
symptoms in allergic adults and children (1-6). Earlier studies have shown that
exposure to allergens in newly diagnosed asthmatic adults is higher than in
randomly selected controls (7,8). Recently Sporik et al. (5) suggested that, in
addition to genetic factors, exposure to HDM allergens in early childhood plays an
important role in the subsequent development of asthma. Therefore, reduction of
environmental HDM concentrations appears to be of clinical and prognostic
relevance in the management of allergic asthma in children.
In a recent study we have found low concentrations of Der p I and Der pI Ii n
floor dust of living rooms and bedrooms of asthmatic children (9). These HDM
levels were remarkably lower than previously reported in studies from other
countries with a similar climate (5,8,10). The lower concentrations of Der p I and
263. HDM exposure in asthmatic and healthy children
Der p II in our study may have been the result of either advice given in former
years to reduce allergen exposure or a general lower concentration of HDM in
houses of this generation of children. We therefore investigated whether we could
find a difference in HDM concentrations in living rooms and bedrooms between
allergic asthmatic children and age and sex matched healthy children. We
compared types of carpeting, cleaning frequencies, age of the houses, humidity, and
amounts of fine dust and HDM concentrations in floor dust.
Patients and Methods
We studied 25 allergic asthmatic and 25 healthy children, all attending primary
school. The 25 consecutively selected asthmatic children visited the outpatient
clinic for pediatric pulmonary diseases at our University Hospital. Routine
standardised information with regard to reduction of environmental allergens was
given previously by pediatricians and specially trained nurses at our outpatient
clinic. These advices were given during the first visit and focused on HDM
reduction in bedrooms.
Age and gender were simular between patients and controls (age: asthmatic
children 9.1 ± 1.4 yrs, healthy controls 9.2 ± 2.1 yrs; gender (male/female):
asthmatic children 14/11, healthy controls 15/10). Children with asthma were
allergic to HDM, defined as a RAST ³ class 3 (Pharmacia Diagnostics, Uppsula,
Sweden) and had increased airway responsiveness, defined as a histamine
provocation concentration (PC20 histamine) less than or equal to 16 mg/ml (2 min
inhalation) (11). No acaricides, matress coverings or dehumidifiers were used in the
investigated houses. All patients used inhaled corticosteroids, twice daily 200 or
400 µg, and short-acting ß2-adrenergic drugs when needed. Short-acting ß2-
adrenergic drugs were withheld 8 h before the lung function measurements. A
healthy classmate living in the same area of the city, was asked to participate in the
study as a control. Controls never had respiratory complaints such as wheezing,
dyspnea, or cough and were never diagnosed as allergic and/or asthmatic. In
addition their first-degree relatives did not suffer from either asthma or any other
allergic disease. All healthy children had normal total IgE values (12) and normal
spirometric lung function values. Two children in the control group had increased
RAST values (HDM 67, grass 8.5, dog 0.7 PRU/ml and grass 1.3, dog 16.6
PRU/ml) but were asymptomatic, and therefore included in the study. Analysis
with and without these two controls showed no differences. Four children (4/25 =
16%) refused venous puncture and spirometry.
The study was approved by the Medical Ethics Committee of our hospital.
Study Design
The homes of the children were visited between March to May in the same year.
27Measurements in the houses of patients and their controls were performed on the
same day.
Methods
The way of carpeting, frequency of cleaning of living rooms and bedrooms, and
the age of the houses were recorded on a checklist. Smooth floor-coverings were
defined as hard floors that could be cleaned wet, while carpeted floor-coverings
were defined as wall-to-wall carpeted floor-coverings either from synthetic, wool,
or cotton material.
All floor dust samples were obtained by the same technician, using a vacuum
cleaner (Phillips type T580, 1100 W). For every location a separate double-walled
disposable paper bag was used (13). Dust was collected from the total area of the
location in order to obtain a representative sample, vaccuum cleaning time per
square meter was according the WHO International standards (14,15). The total
amount of fine dust of each sample was measured after filtering with a 355-µm
aperture sieve. Each sample was analyzed for the amount of HDM, and the
concentration expressed in µg/g of fine dust according to the WHO International
standards (14,15). The HDM allergens Der p I and Der p II were analyzed by
sandwich immunoassays using monoclonal antibodies (16). A reference HDM
extract was used, which was calibrated for the content of Der p I and Der pI Ib y
the Allergy Division of the Dutch Central Laboratory of the Blood Transfusion
Service (Amsterdam), in serial dilutions for calculation of the allergen content of
the HDM samples. The controlled samples in this reference laboratory resulted in
comparable HDM concentrations. Air temperature and relative humidity were
measured to obtain absolute humidity values (gram water vapor per kilogram of
dry air) in each location.
Pulmonary Function Measurements
Spirometry (inspiratory slow vital capacity (IVC) and forced expiratory value in
one second (FEV1)) was performed with a water sealed spirometer (Lode BV,
Groningen, The Netherlands). Peak expiratory flow (PEF) measurements were
performed with a Wright peak flow meter. The best of three efforts was used for
statistical analysis. Normal values from Zapletal et al. were used (17).
Statistical Analysis
Statistical analysis was performed by SPSS/PC, version 4.0 (SPSS Inc, Chicago,
IL, USA). Variables with a Gaussian distribution are presented as means ± SD.
Variables with a non-Gaussian distribution (HDM allergen concentrations) are
presented as medians with minimum and maximum values. Differences were
calculated by paired t tests and by nonparametric tests (Mann-Whitney U)a s
appropriate. Differences in discontinuous variables were calculated by Chi-squared
tests. Correlations were calculated by Spearman’s rank correlation coefficient. A p
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value of < 0.05 was accepted as significant. When the amount of fine dust was less
than 0.1 g per location, we used the 0.1 g values for calculations. When the
allergen load was below detection concentration, we used the detection
concentration (0.01 µg/g for Der p I and Der p II) for calculations. HDM values
below detection concentration were not overestimated due to nonparametric testing.
Results
Total IgE, specific IgE to HDM and total number of eosinophils were significantly
higher (p < 0.05) in the asthmatic children compared to the healthy children (total
IgE: 359 (78 - 7699 IU/ml) versus 52 (4 - 674 IU/ml); specific IgE to HDM: 17.3
(2.1 - 180 PRU/ml) versus 0 (0 - 67.0 PRU/ml); eosinophils: 5.0 ± 3.4 10
8/l versus
2.9 ± 2.0 10
8/l). Lung function values were similar between the two groups.
Cleaning frequency of the living rooms were similar (asthmatic children: 3.5 (1 - 7)
times per week, healthy children 2.5 (1 - 7) times per week). Cleaning frequency of
the bedrooms was significantly higher in asthmatic children compared to healthy
children (2.0 (1 - 7) times per week versus 1.0 (1 - 7) times per week, p < 0.05).
The ages of the houses were similar (asthmatic children 20 (3 - 100 yrs), healthy
children 20 (1 - 141 yrs). No significant correlation was found between cleaning
frequency or age of the buildings on one hand and the amount of fine dust or
allergen concentrations of both locations of the asthmatic and healthy children on
the other hand.
We observed comparable types of floor-coverings in living rooms of both groups
of children (smooth floor-coverings in asthmatic group: 9/25=36%; in the healthy
group 8/25=32%), but significantly more smooth floor-coverings in the bedrooms
of the asthmatic children (10/25 = 40%) than in the bedrooms of the healthy
children (3/25 = 12%). In 2 bedrooms (1 asthmatic and 1 healthy child) we
collected less than 0.1 g fine dust. These samples were not analysed for HDM.
The amount of fine dust/m
2 floor space in the living rooms of the asthmatic group
was significantly higher (p < 0.05) than in the bedrooms. We did not observe this
difference in the group of healthy children (Table 1). In the bedrooms of the
asthmatic children significantly less (p < 0.05) fine dust was found on smooth
floor-coverings than on carpeted floor-coverings, this difference being almost
significant in the control group (p = 0.09). Smooth floor-coverings (measured for
all children) contained less dust per squaremeter floor space than carpeted floor-
coverings in general, in the separate locations, and in both study groups (Table 2).
The Der p I and Der p II concentrations in floor dust (Figure 1) were similar in
living rooms and bedrooms, and no significant differences were found between the
locations of the asthmatic and healthy children. In all locations some samples
contained Der p I concentrations above international safety standards (14,15): in
29the asthmatic group: 6 above 2 µg and 6 above 10 µg Der p I /g of fine dust; in the
control group 7 above 2 µg and 6 above 10 µg Der p I /g of fine dust.
Table 2 shows the relationship of type of floor-covering to HDM concentrations
per location expressed in µg/g of fine dust for Der p I and Der p II. Smooth floor-
coverings contained significantly less Der p I than carpeted floor-coverings in
general (measurements of all children), in the different locations and in both study
groups (Table 2). The same was true for Der p II in the living rooms of both
groups and in the bedrooms of the healthy children, as well as for the levels of Der
p II on smooth and carpeted floors in the bedrooms, and in all combined locations
of the asthmatic children.
When Der p I and Der p II are expressed in µg/m
2 floor space, all comparisons in
Table 2 showed significantly less allergen in favour of smooth floors (p < 0.01).
No significant differences in humidity were found between living rooms and
bedrooms of both groups of children. Values in the living rooms were 7.2 ± 0.9
g/kg and 7.7 ± 0.9 g/kg and in the bedrooms 6.2 ± 0.6 g/kg and 6.5 ± 1.1 g/kg, for
the asthmatic and healthy children respectively. Absolute humidity in the bedrooms
was significantly lower than in the living rooms in both groups. We did not find
any significant correlation between absolute humidity and HDM allergen
concentrations.
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3
1TABLE 2 Amount of fine dust and house dust mite exposure in the locations by type of
floor-covering
’smooth’ ’carpeted’
All locations (n = 30) (n = 70)
Dust, g/m
2 0.04 (0.01 - 0.29) 0.14 (0.01 - 1.93)*
Der p I 0.4 (n.d. - 33.0) 1.5 (n.d. - 68.8)*
Der p II 0.09 (n.d. - 13.3) 0.9 (n.d. - 59.7)*
All living rooms (n = 17) (n = 33)
Dust, g/m
2 0.07 (0.01 - 0.29) 0.16 (0.02 - 1.81)*
Der p I 0.3 (n.d. - 33.0) 1.6 (0.03 - 59.4)*
Der p II 0.09 (n.d. - 13.3) 0.6 (n.d. - 14.7)*
All bedrooms (n = 13) (n = 37)
Dust, g/m
2 0.02 (0.01 - 0.19) 0.13 (0.01 - 1.93)*
Der p I 0.4 (n.d. - 13.5) 1.1 (n.d. - 68.8)*
Der p II 0.09 (n.d. - 9.4) 1.0 (n.d. - 59.7)1
All AAC locations (n = 19) (n = 31)
Dust, g/m
2 0.03 (0.01 - 0.27) 0.14 (0.01 - 1.81)*
Der p I 0.4 (n.d. - 33.0) 1.1 (0.06 - 59.4)*
Der p II 0.10 (n.d. - 13.3) 0.5 (n.d. - 14.7)
All NAC locations (n = 11) (n = 39)
Dust, g/m
2 0.06 (0.17 - 0.29) 0.16 (0.01 - 1.93)*
Der p I 0.3 (n.d. - 1.7) 1.7 (n.d. - 68.8)*
Der p II 0.08 (0.01 - 4.1) 1.0 (n.d. - 59.7)*
Valuesareexpressedasmedian
(minimum - maximum ) value, significant differences by Mann-Whitney U test. AAC:
allergic asthmatic children, NAC: non-asthmatic children. Der p I and Der p II are expressed
as µg/g fine dust. *: p < 0.05 between carpeting. 1: p = 0.06 between carpeting.
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Figure 1 Der p I per gram of fine dust (µg/g) (upper panel), and Der p II per gram of fine dust
(µg/g) (lower panel) in living rooms and bedrooms. Circles: values of the allergic asthmatic children
(AAC), triangles values of the non-asthmatic children (NAC). --- : median value.
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We did not observe significant differences in Der p I and Der p II exposure between asthmatic and
healthy children. As expected, smooth floors contained significantly lower Der p I and Der pI I
concentrations than carpeted floors.
The house dust mite (HDM) exposure levels were low as compared to those reported from other
countries with a similar climate (5,8,10), confirming our previous findings (9). In that report, we
hypothesised that the observed lower exposure concentrations were the result of previously given
routine advice with regard to preventive measures to reduce HDM exposure. The results of this study
reject this hypothesis.
Bedrooms of the asthmatics had significantly more frequent smooth floor-coverings than the control
group and therefore contained less dust. When all smooth floor-coverings were compared with all
carpeted floors we indeed observed significantly lower HDM concentrations on smooth floor-
coverings. Although we observed that bedrooms of asthmatic children were more frequently cleaned,
we could not find a correlation between cleaning frequency and the amount of fine dust or allergen
concentrations.
High concentrations of HDM may be an important risk factor for both development and the severity
of asthmatic symptoms in sensitized children (5,18). Our observation indicates that parents, probably
as a result of former advice, focus on adjusting the type of floor-covering in the bedrooms of their
children. This is in line with findings in Denmark (19), where houses of non-allergic individuals
contained significantly higher amounts of cat allergen than houses from allergic individuals.
Our study shows that smooth floor-coverings are associated with less dust and lower HDM
concentrations. It is known that HDM flourish at higher temperature and humidity, suggesting that
reduction of humidity is important in the battle against HDM. We observed no differences in absolute
humidity between the houses of the two study groups, and especially not in the bedrooms. This does
not imply that humidity is not important. Korsgaard (7) found a higher number of HDM and a higher
absolute humidity in his asthmatic group than in the control group. Absolute humidity values in his
and our study are comparable. Moreover, we could not confirm the observed correlation between
humidity and allergen concentrations. A difference between his and our study is that we only
measured humidity at one point of time. Furthermore, measurements in the Danish study were
performed in November and December, while our measurements took place from March to May. It
may well be that humidity differences may exist at other times of the year.
We did not observe significant differences in Der p I and Der p II concentrations between asthmatic
children and their controls in bedrooms and living rooms. According to the international standards for
preventive measures to reduce HDM exposure, a concentration of 2 µg Der p I /g of fine dust should
be a risk factor for sensitisation, and a concentration of 10 µg Der p I /g of fine dust a major risk
factor for acute asthma in mite allergic individuals. Although the median values of Der pIi no u r
study were rather low, in both types of locations some sample concentrations (14/100 = 14%) were
above 10 µg Der p I /g of fine dust. Seventy-six percent of the allergic asthmatic children with
maintenance medication of inhaled corticosteroids, were exposed to lower concentrations of Der pI
than 2 µg/g of fine dust in living room and/or bedroom. This indicates that lower concentrations of
Der p I are also of importance to the clinical expression of the disease (20), and that the international
recommendations should be revised. The low HDM concentrations from our pediatric population are
in accordance with observations in houses of adults from our region (16), and a recent publication on
HDM concentrations from more southern regions in the Netherlands (18). Despite the observed lower
HDM concentrations, all Dutch studies report a large individual variation. It seems, therefore,
worthwhile to verify individual HDM concentrations in these locations and relate them to allergen
reduction measures.
343. HDM exposure in asthmatic and healthy children
We conclude that the observed low HDM concentrations in Dutch dwellings are a general finding in
this generation of children. We have observed a higher cleaning frequency, and a higher prevalence of
smooth floor-coverings in bedrooms of asthmatic children than of healthy children, yet HDM
concentrations were not significantly different. The latter can be explained by the observation that
only 40% of the asthmatic children had smooth floor-coverings in their bedrooms. Finally we confirm
previous data in that smooth floor-coverings contain less fine dust and lower concentrations of Der pI
and Der p II.
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The influence of exogenous factors in the home on the circadian variation of
airway obstruction has not been fully assessed in children with asthma. The aim of
the study was to investigate the contribution of exogenous stimuli to the degree of
peak expiratory flow (PEF) variability during 24 h. Fifty-five children (33 boys and
22 girls; mean age 9.3 ± 1.7 yrs) with symptoms of asthma, increased bronchial
responsiveness and a solitary allergy to house dust mite (HDM) participated. Their
asthma symptoms were well-controlled for at least 4 mo with daily inhaled
corticosteroids (ICS) and ß2-adrenergic drugs if needed. Symptoms, peripheral
blood eosinophils, total IgE, and specific IgE to HDM were assessed. Spirometry
and PC20 histamine were performed. PEF amplitudes during 24 h (highest minus
lowest as a percentage of day’s mean value) were obtained at home during and 6 d
after withdrawal of ICS. Dust samples were collected from the total area of the
living rooms, bedrooms, mattresses (n = 25), and classrooms to obtain the HDM
allergen (HDMA) exposure to Der p I and Der p II. Family smoking habits,
presence of pets, and types of floor-covering were recorded on a checklist. Mean
PEF amplitude did not increase after withdrawal of ICS, but absolute PEF values
were significantly lower (p = 0.05) at midnight and 4:00 a.m. Twenty-six children
(47%) were exposed to environmental tobacco smoke (ETS), 23 (42%) kept pets.
Mattresses contained significantly higher amounts of HDMA compared with other
locations. PEF amplitude after withdrawal of ICS was significantly higher in
children exposed to ETS, a pet, or a high HDMA level in their mattress than in
children who were not exposed (ETS: 29.7% [3.9-56.6] versus 19.4% [0.0-56.6], p
< 0.05 ; pets: 31.4% [9.7-52.5] versus 21.9% [0.0-56.6] p < 0.05; high HDMA
level in the mattress 35.5% [10.2-56.6] versus 21.4% [3.9-56.6] p < 0.05). These
factors combined with age, PC20 histamine and its interaction with ETS, especially
in mild to moderate asthma, explained 48.4% of the variance of the PEF amplitude
after withdrawal of ICS. Exogenous stimuli such as exposure to ETS, pets, and
high HDMA levels in mattresses contribute to an increased circadian PEF
amplitude after withdrawal of ICS and therefore to nocturnal worsening of asthma
in HDM-allergic asthmatic children. Moreover, ETS exposure seems especially to
worsen PEF variability in children with mild to moderately severe bronchial
responsiveness.
Introduction
Nocturnal airflow limitation is a common feature in children with asthma and its
underlying pathophysiology has only partially been solved. Several endogenous
factors such as circulating adrenaline and vagal activity (1,2), and exogenous
factors such as exposure to tobacco smoke and to allergens may contribute to the
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severity of asthmatic symptoms in children during the night. Allergen exposure
seems especially important, because it has been shown that allergen provocation
may increase circadian peak expiratory flow (PEF) variation for weeks on end (3).
In an earlier study, we have observed a worsening of nocturnal PEF values after
withdrawal of anti-inflammatory maintenance medication at home in children with
allergic asthma (4). When these same children were admitted to a hospital and their
medication was subsequently withdrawn, the opposite happened, i.e., nocturnal lung
function values improved. This suggested that environmental stimuli (at home)
contributed to the increased circadian swings in airway diameter after withdrawal
of medication. Next to allergens, other factors such as environmental tobacco
smoke (ETS) are known to contribute to increased airway obstruction (5,6).
Therefore, the contribution of exogenous stimuli in the home to an increased
circadian PEF amplitude after withdrawal of anti-inflammatory medication was
investigated. We assessed associations of PEF amplitude with exposure to ETS,
pets, and house dust mites (HDM) in a group of asthmatic children with a solitary
allergy to HDM.
Patients and methods
Patients
Fifty-five asthmatic children (33 boys, 22 girls; mean age, 9.3 ± 1.7 yrs) visiting
primary school were included. All were characterized by symptoms of asthma, an
increased total IgE, and specific IgE to HDM (RAST class ³ 3; Pharmacia
Diagnostics, Uppsala, Sweden). None had increased specific IgE to dog, cat, tree,
grass, or milk (RAST class = 0; Pharmacia Diagnostics) in order to exclude
interference with other allergies and to obtain a more homogeneous population. All
children had a forced expiratory volume in one second (FEV1) as percentage of the
predicted value ³ 70% and increased bronchial responsiveness (histamine
provocation concentration £ 8 mg/ml causing a fall of 20% or more in FEV1 from
baseline value). Symptoms were well-controlled with maintenance inhaled
corticosteroids (ICS) for at least 4 mo before the study, twice daily 200 µg or 400
µg, and ß2-adrenergic drugs when needed. Routine standardized information with
regard to reduction of environmental allergens was given previously by the
pediatrician and/or specially trained nurse at our outpatient clinic. Acaricides,
mattress encasings, and dehumidifiers were not used in the investigated houses.
Informed consent from all children and their parents was obtained, and the study
was approved by the Medical Ethics Committee of our hospital.
Study Design
Daytime and nighttime symptoms were recorded during the 3 wk before
withdrawal of ICS. At the end of the 3-wk period, a home and school visit was
39made to collect house dust from living rooms, bedrooms, mattresses, and
classrooms. Mattress samples were only collected from 25 of the 55 included
children. Family smoking habits, presence of pets in the household, and type of
floor-coverings were recorded on a checklist. Temperature and relative humidity
were measured in each location to obtain absolute humidity (gram water vapor per
kilogram of dry air).
At the outpatient clinic, a blood sample was drawn to determine eosinophil count,
total IgE, and specific IgE to HDM; spirometry and a histamine inhalation
challenge test were performed during treatment with ICS.
The circadian PEF amplitude (highest minus lowest PEF value expressed as
percentage of the day’s mean value) was obtained at home on two days: one day
during ICS and on the sixth day after withdrawal of ICS. All measurements were
performed in three consecutive years, from August to November.
Clinical Characteristics of the Subjects
SYMPTOMS: Symptoms of cough, wheeze, dyspnea, and phlegm production
during the day and at night were recorded in a diary on a 4-points scale (0: no
symptoms, 1: mild, 2: moderate, 3: severe) (7). Daily symptoms were recorded and
added up during the 3-wk period to obtain total symptoms during daytime and
nighttime during ICS. Symptoms were also recorded during daytime and nighttime
on the sixth day after withdrawal of ICS.
LUNG FUNCTION AND PROVOCATION TESTING: PEF measurements were
performed at home, every 4 h during 24 h, in an upright position with a mini-
Wright peak flow meter. The best of three efforts was used for statistical analysis.
FEV1 and inspiratory vital capacity (IVC) were measured with a water-sealed
spirometer (Lode BV, Groningen, the Netherlands). At least three reproducible
values (i.e.<5%difference among the recordings) were obtained; the highest was
used in the analysis. Airway histamine challenge tests were performed during ICS
with a gauged DeVilbiss 646 nebulizer (DeVilbiss, Somerset, MA, USA), with an
output of 0.13 ml/min according to the modification method of Cockcroft and
colleagues (8). A 0.9% phosphate-buffered saline solution and doubling histamine
concentrations from 0.03 to 16 mg/ml were inhaled for 2 min during tidal
breathing, with the nose clipped, at 5-min intervals, until FEV1 had fallen by 20%
from the initial value. The exact provocation concentration of histamine that
induced a 20% fall in FEV1 (PC20) was assessed by a log-dose response curve. ß2-
Adrenergic drugs were withheld 8 h before the measurements.
LABORATORY INVESTIGATIONS: Total IgE and specific IgE were quantified
using an enzyme immunoassay procedure (Pharmacia Diagnostics), and expressed
in international units (IU) per milliliter, and Phadebas RAST units (PRU) per
milliliter, respectively.
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Exogenous Stimuli
All dust samples were obtained by the same technician, using a vacuum cleaner
(Phillips type T580, 1100 W). For every location, we used a different double-
walled disposable paper bag (9), and a special vacuum cleaner filter for the
mattresses (ALK filter device; surface, 38 cm
2, pore size, 6 µm; ALK allergolic
lab, Hørsholm, Denmark). Dust was collected from the total area of the location in
order to obtain a representative sample. The total amount of fine dust of each
sample was measured after filtering with a 355-µm aperture sieve. Each sample
was analyzed for the amount of HDM allergen (HDMA) (Der p I and Der p II) per
gram of fine dust according to the WHO International standards (10,11). HDMA
were analyzed by sandwich immunoassays using monoclonal antibodies (12).
Smooth (hard) floor-coverings, with or without a small carpet, were defined as
floor-coverings that could be cleaned wet, while carpeted floor-coverings were
defined as wall-to-wall carpeted floor-coverings either from wool, cotton, or
synthetic material.
Statistical Analysis
FEV1 values were expressed as percentage of the predicted value (% pred) (13).
PC20 values were used after logarithmic transformation (base 2), since this reflects
doubling doses and normalized the distribution. Total eosinophils, total IgE, and
specific IgE HDM were logarithmically transformed (base 10) to normalize the
distribution. Skewedness of distribution was assessed with a Kolmogorov-Smirnov
test. If a p value < 0.05 was obtained, nonparametric techniques (Spearman’s rho
for correlation, Mann-Whitney U test to compare group means) were applied to
analyze the data, values being expressed as median (minimum to maximum).
Otherwise, parametric analyses (Pearson’s r for correlation, Student’s t test for
comparison of groups means) were used and values were expressed as mean ± SD.
Total HDMA exposure to Dermatophagoides pteronyssinus was determined by
adding up the HDMA exposure to Der p I/g and Der p II/g. When the HDMA
concentration was below detection level, the detection level (5 ng/g) was used for
calculations. In some locations, we found some dust samples containing HDMA
levels below the detection level (Der p I: living room n = 4, bedroom n = 6,
classroomn=1 2 ;Der p II: living room n = 3, bedroom n = 4, classroom n = 16;
Der p I and II: living room n = 1, bedroom n = 4, classroom n = 4). Association of
type of floor-covering with HDMA exposure (log) was assessed with analysis of
variance (ANOVA). Multiple regression analysis was performed on the PEF
amplitude after withdrawal of ICS (dependent variable) with the following as
independent variables: age (months), histamine responsiveness (log2 PC20), log total
HDMA exposure, ETS exposure, exposure to pets, and the interaction of ETS with
PC20.
A p value of 5% was considered as statistically significant. All analyses were
performed with SPSS/PC+ package, version 4.0 (SPSS Inc, Chicago, Il, USA).
41Results
Clinical Characteristics of the Subjects
Clinical characteristics are presented in Table 1. Frequencies of the reported
symptoms were low, cough being the most common. FEV1 deteriorated
significantly after withdrawal of ICS (during ICS: 92.7 ± 12.4%, after withdrawal
of ICS: 88.3 ± 13.3%, p < 0.05). FEV1/IVC deteriorated, but not significantly, after
withdrawal of ICS (during ICS: 83.1 ± 6.8%, after withdrawal of ICS: 81.3 ±
8.9%). Absolute PEF values during treatment with ICS showed a circadian pattern,
with highest values in the afternoon (noon: 317 ± 10 l/min) and lowest values
during the night (midnight: 282 ± 11 l/min). Absolute PEF values after withdrawal
of ICS at midnight and 4:00 a.m. decreased significantly (midnight: 282 ± 11 l/min
to 267 ± 10 l/min, p = 0.05; 4:00 a.m.: 283 ± 11 l/min to 269 ± 10 l/min, p =
0.05). The PEF amplitude correlated, both during and after withdrawal of ICS,
significantly with daytime and nighttime symptoms during ICS. The PEF amplitude
after withdrawal of ICS correlated inversely with PC20 and positively with the
eosinophil count (Table 2).
Exposure to Exogenous Stimuli
Twenty-six (47%) children were exposed to ETS because of smoking habits from
their mother and/or father. Maternal smoking was reported in four families (7%),
paternal smoking in nine families (16%), and both parents smoked in 13 families
(24%). Pets were present in 23 (42%) households: dog (n = 8; 15%), cat (n = 5;
9%), dog and cat (n = 6; 11%), guinea pig (n = 3; 5%) and a bird (n = 1; 2%).
From 25 children, dust samples of the mattresses were collected as well. These 25
children did not differ from the other 30 children with regard to their clinical
variables. Of these 25, 14 (56%) were exposed to an HDMA level higher than
10,000 ng/g of fine dust in their mattresses. Eleven children (11/25 = 44%) were
exposed to HDMA levels in their mattresses below 10,000 ng/g of fine dust.
Exposures to Der p I and Der p II in each location and per type of floor-covering
are presented in Figure 1. Mattresses contained the highest HDMA exposure levels,
and classrooms had lowest HDMA exposure (p < 0.001). In 80% of the cases (n =
20), mattresses had the highest HDMA exposure levels compared with the other
locations (living rooms: 12% [3 of 25], bedrooms: 8% [2 of 25]). A significant
difference in HDMA exposure was observed between the types of floor-covering in
living rooms and classrooms. The lowest values were measured on smooth floor-
coverings and highest on smooth floor-coverings with a small carpet on it.
No significant differences in HDMA exposure levels were found between
households with and without pets. No significant correlations between HDMA
exposure levels at any location and absolute humidity levels were found.
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Relation of Exogenous Stimuli with PEF Amplitude
There were no significant correlations found between the magnitude of the PEF
amplitude and HDMA exposures for each location separately or when expressed as
all locations combined (Spearman’s rho between -0.10 and 0.05 during ICS, and
between 0.03 and 0.18 after withdrawal of ICS; p> 0.05). Children exposed to
ETS, pets, or high HDMA levels (>10,000 ng/g of dust) in their mattresses or to
combinations of these stimuli had significantly higher PEF amplitudes after
withdrawal of ICS than the nonexposed children (Table 3). This was not found
during ICS. Figure 2 shows that the mean PEF amplitude after withdrawal of ICS
was higher with increasing numbers of different exogenous factors. The largest
amplitude was present in those exposed to the combination of ETS, pets, and high
HDMA in the mattress.
Multiple Regression Analysis on PEF Amplitude
The results of multiple regression analysis of PEF amplitude after withdrawal of
ICS (R
2 = 48.4%, p = 0.000) are shown in Table 4. Exposure to ETS, pets, and
HDMA, the interaction of exposure to ETS with PC20,P C 20 and age were
significantly contributing variables.
The interaction between PC20 and ETS indicates a larger PEF amplitude after
withdrawal of ICS in children exposed to ETS when they had moderate to mild
bronchial responsiveness (those with a PC20 higher than the median PC20 value [0.8
mg histamine/ml]). (PC20 > 0.8 mg/ml: no ETS 16.6% [7.3 - 33.2], with ETS
29.6% [3.9 - 52.1], p = 0.05; PC20 £ 0.8 mg/ml: no ETS 26.8% [0.0 - 56.6], with
ETS 31.9% [12.4 - 56.6], p = 0.46).
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During ICS After withdrawal of ICS
Male / female 33 / 22
Age, yrs 9.3 ± 1.7
Daytime symptoms
Wheeze 0 (0 - 52) 0 (0 - 3)
S O B 1( 0- 5 7 ) 0( 0- 3 )
Cough 5 (0 - 60) 0 (0 - 3)
Phlegm 0 (0 - 37) 0 (0 - 3)
Total symptom score 12 (0 - 206) 1 (0 - 11)
Nighttime symptoms
Wheeze 0 (0 - 49) 0 (0 - 3)
SOB 0 (0 - 48)** 0( 0- 3 )
Cough 2 (0 - 53)** 0( 0- 3 )
Phlegm 0 (0 - 15) 0 (0 - 2)
Total symptom score 5 (0 - 150)* 0 (0 - 11)#
FEV1 % pred, % 92.7 ± 12.4 88.3 ± 13.3*
FEV1/IVC, % 83.1 ± 6.8 81.3 ± 8.9##
PEF amplitude, % 26.4 ± 18.8 26.9 ± 14.7
PC20, mg/ml 0.80 (0.02 - 15.7)
Eosinophils, 10
6/l 610 ± 437
Total IgE, IU/ml 379 (17 - 5,782)
Specific IgE HDM, PRU/ml 38 ( 4 - 377)
Values are expressed as mean ± standard deviation or median (minimum - maximum)
depending on the skewedness of the distribution. SOB: shortness of breath, ICS: inhaled
corticosteroids, HDM: house dust mite. Differences were calculated by Student’s t test or
Mann-Whitney U test depending on the skewedness of the distribution. : during ICS
symptoms were scored during 3 weeks, after withdrawal of ICS symptoms were scored on
1 day. **: p = 0.01 between daytime and nighttime symptoms; *: p = 0.02 between
daytime and nighttime symptoms or FEV1 during and after withdrawal of ICS; #:p=
0.06 between daytime and nighttime symptoms; ##: p = 0.09 during versus without ICS.
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TABLE 4 Explaining model for the PEF amplitude (n = 55) after withdrawal of inhaled
corticosteroids (R
2: 48.4%, p = 0.000)
ß p value
Constant 17.9 0.19
Pets in the household 9.8 0.004
Exposure to ETS 11.2 0.001
Log house dust mite exposure in living room,
bedroom and classroom 7.5 0.006
Interaction between ETS and log2 PC20 4.5 0.008
Log2 PC20 5.1 0.07
Age, months -0.2 0.003
ETS: environmental tobacco smoke.
47Figure 1 House dust mite allergen exposure to Der p I and Der p II per gram of fine dust in
living rooms, bedrooms, mattresses, and classrooms (median value with ranges). Results are given
per location for all samples (black bars) and per type of floor-covering: smooth floor-covering
(open bars), synthetic wall-to-wall carpets (/// bars), woolen or cotton wall-to wall carpets (\\\
bars), smooth floor-covering with carpet on it (horizontal striped bars). The number of samples is
given on top of each bar. *: significantly higher or lower (p < 0.001) compared with other type of
floor-coverings. There was a significant difference in HDMA exposure per type of floor-covering
(## living room, p < 0.001 and # classroom, p < 0.05; ANOVA).
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Figure 2 PEF amplitude after withdrawal of inhaled corticosteroids (ICS). Bars represent the
results (median value with ranges) of all children. All = all children; E- P- = not exposed to
environmental tobacco smoke (ETS) and pets; E+ = exposed to ETS; P+ = exposed to pets; E+ P+
= exposed to ETS and pets; M+ = exposed to high HDMA level (> 10,000 ng /g) in mattress; E+
P+ M+ = exposed to ETS; pets and high HDMA level in mattress. The number of samples is
given on top of each bar.
49Discussion
This study demonstrates a significant association between exposure to exogenous
stimuli and an increased circadian PEF amplitude after withdrawal of inhaled
corticosteroids (ICS) in allergic asthmatic children. Environmental tobacco smoke
(ETS), pets and high exposure to house dust mite allergens (HDMA) in bedding
contributed independently to a higher PEF amplitude after withdrawal of ICS.
Multiple regression analysis showed that these exogenous stimuli explained 48.4%
of the variation in PEF amplitude after withdrawal of ICS together with the
interaction of ETS with PC20,P C 20 itself, and age. Although the PEF amplitude in
the total group hardly increased after withdrawal of ICS, nocturnal PEF values (at
midnight and 4:00 a.m.) decreased significantly. Finally, highest HDMA exposure
levels were found in mattresses and on smooth floor-coverings with a carpet,
lowest HDMA levels on smooth floor-coverings.
The results of our study are in agreement with epidemiologic studies suggesting
that exposure to ETS may have adverse effects on children’s pulmonary function.
The lower pulmonary function values among schoolchildren were found to be
associated with maternal smoking as a consequence of the combination of a
persistent deficit related to earlier (including in utero) exposure and an additional
deficit related to current exposure (14). This indicates that ETS has not only a
short-term effect, but long-term exposure is even of greater importance. Frischer
and associates (5) observed a negative effect of ETS on diurnal PEF variability in
non-allergic asthmatic and normal children, but could not confirm this for allergic
asthmatic children. They hypothesized that mothers tended to change their smoking
habits subsequent to the development of disease in their allergic children. However,
no data on the treatment in these asthmatic children were presented. Our study
shows a larger effect of ETS after withdrawal of ICS. Thus, the lack of correlation
in the study of Frischer and associates (5) can be explained when allergic children
in the study used anti-inflammatory drugs, which is plausible given the consensus
on their use in asthma treatment. We do now show that withdrawal of ICS results
in a large PEF amplitude especially in those asthmatic children who are regularly
exposed to ETS.
The relationship between ETS and bronchial responsiveness is conclusive (15,16).
Even in young normal children, parental smoking contributes to increased bronchial
responsiveness (17). O’Connor and coworkers (15) investigated the relationship
between passive cigarette smoking and non-specific bronchial responsiveness in a
population-based sample of children and young adults. They found a borderline
significant relationship between bronchial responsiveness and maternal smoking in
asthmatic young adults but not in similarly aged non-asthmatics, despite the
occurrence of lower FEV1 and FEF25-75 values in this group. In our asthmatic
children, we did not measure bronchial responsiveness to an inhaled
bronchoconstricting agent before and after withdrawal of ICS. We found a
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significant interaction of ETS and PC20 with regard to PEF amplitude after
withdrawal of ICS: children with mild to moderate bronchial responsiveness had a
larger PEF amplitude when exposed to ETS. It is widely known that cessation of
ICS is associated with a deterioration of bronchial responsiveness, in which airway
inflammation is thought to be the underlying mechanism. It seems attractive to
hypothesize that the interaction of ETS and bronchial responsiveness during ICS
occurs via increased inflammation, ultimately resulting in higher PEF variability
and unstable asthma, as suggested by the larger PEF amplitude 6 d after
withdrawal of ICS in the ETS-exposed group. It may well be that the effect of ETS
is minimal when airway inflammation is extremely active as can be expected in
children with very severe bronchial responsiveness towards exogenous stimuli.
Children with pets in their households had a larger increase in their PEF amplitude
after withdrawal of ICS. Allergies to animals in households, such as cats and dogs,
are common. Antigens from virtually any animal, including exotic species, may
produce allergic symptoms (6). Notwithstanding the exclusion of children with an
allergy to cats and dogs, we found that the exposure to pets in the household
negatively affected the PEF variation after withdrawal of ICS. An explanation for
this observation in children with a solitary allergy to HDM may be that HDMA are
more airborne due to air disturbance of pets, resulting in a higher airway
provocation. Swanson and colleagues (18) described a good correlation between
airborne and settled dust samples, but they did not look for the influence of air
disturbance by pets. Another explanation for the larger PEF amplitude after
withdrawal of ICS in the children with pets in their household may be that the
development of specific IgE to cats and dogs is slower than the development of
clinical symptoms. It is also possible that the influence of pets and ETS on PEF
amplitude and bronchial responsiveness is due to cross-reactive priming, by which
exposure to non-specific antigens leads to priming of bronchial responsiveness and
PEF amplitude. The magnitude of the effects seen in this investigation are
physiologically small but plausible because of chronic low-dose exposure to
multiple potential exposure factors.
Children exposed to high HDMA levels in their mattresses (>10,000 ng/g of dust)
had a significant higher PEF amplitude after withdrawal of ICS than those exposed
to lower HDMA levels in their mattresses. The recognition that HDM faecal pellets
are the source of the antigen causing HDM allergy has led to the suggestion that
intensive contact with mites in bedding might precipitate airway obstruction at
night (19). The mattress was the highest source of HDMA exposure in 80% of our
population. This percentage is comparable with other observations in children (60
to 73%) (20), and much higher than in adults (21). Gervais and associates (3)
previously described an increased reactivity to HDM at night. Our current
observations indicate that, together with the well-known increased responsiveness
to HDM overnight, exposure to high HDMA levels from mattresses may contribute
to an increased nocturnal airway obstruction. Opposite to our findings, other studies
51found that HDMA exposure from mattresses was not significantly higher than in
the other locations. An explanation for the discrepancy with our findings might be
that the HDMA exposure in the living rooms, bedrooms and classrooms in our
study are low and lower than in most other reports (20,22,23).
Smooth floor-coverings generally contain the lowest HDMA levels. An interesting
observation in our study is that the highest HDMA levels were found on smooth
floors with a small carpet on it, being even higher than in woolen carpets. Zock
and colleagues (24) showed higher diurnal PEF variations with higher HDMA
levels collected from carpeted floors. Their results as well as ours emphasize the
importance of the contribution of HDMA exposure to the subsequent development
of nocturnal airway obstruction in HDM-allergic individuals. Moreover, results of
both studies indicate that HDMA avoidance measures in HDM-allergic children
with nocturnal airway obstruction should be focussed on high HDM sources such
as mattresses and carpets, both wall-to-wall and small ones.
We conclude that exposure to exogenous factors such as ETS, pets, and high
HDMA levels in mattresses contribute independently to an increased PEF
amplitude after withdrawal of ICS in allergic asthmatic children. Finally, ETS
seems especially to worsen PEF variability in children with mild to moderate
bronchial responsiveness.
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The aim of the study was to investigate whether seasonal differences in house dust
mite (HDM) allergen exposure influence the circadian peak expiratory flow (PEF)
amplitude in asthmatic children. Asthmatic children (n = 25) with a solitary allergy
to HDM were studied in spring and in autumn. All used inhaled corticosteroids
(ICS) regularly. Six days after withdrawal of ICS PEF amplitude (every 4 h during
24 h, highest minus lowest as a percentage of day’s mean value) was assessed.
HDM allergen (HDMA) in living rooms, bedrooms and mattresses were collected.
HDMA levels were not always highest in autumn. PEF amplitudes in spring and
autumn did not correlate with HDMA levels in the same season. However, the
seasonal difference in PEF amplitude (autumn value minus spring value) correlated
positively and significantly with the seasonal difference in HDMA exposure levels
from the mattresses (rho = 0.34, p < 0.05). Multivariate analysis showed that the
seasonal difference in HDMA exposure in the mattress was the single parameter
explaining seasonal difference in PEF amplitudes by 21.0% (p = 0.02). Our cross-
sectional study showed a higher PEF amplitude not to be significantly associated
with higher HDMA exposure in mattresses in a group of HDM-allergic asthmatic
children. However, the change in HDMA exposure over seasons contributed
significantly to the change in PEF amplitude after withdrawal of ICS in HDM-
allergic asthmatic children.
Introduction
Natural indoor exposure to house dust mites (HDM) allergens is known to vary
from season to season (1), although its variation is much less pronounced than
exposure to pollen allergens. HDM inhalation in HDM-allergic individuals may
result in an early and late asthmatic response, often followed by increased airway
obstruction for many nights (2,3). Reduction of environmental allergens has been
shown to improve the disease (4), and may result in a decrease of the circadian
peak expiratory flow amplitude.
Little data are available with respect to the influence of a change in natural
exposure levels of HDM allergens (HDMA) on clinical relevant variables.
Although many clinicians in our part of the world have the impression that asthma
deteriorates during autumn in many patients, the HDM season, it is not known
whether seasonal variations in exogenous stimuli such as HDMA levels are
associated with seasonal differences in PEF amplitude. In an earlier study we have
found that exogenous factors such as HDMA exposure, environmental tobacco
smoke and the presence of pets contributed to the magnitude of the circadian PEF
amplitude measured in one season of the year (5).
In this study we further explored whether the seasonal difference in HDMA
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exposure contributes to an increase in circadian PEF amplitude in asthmatic
children with a mono-allergy to HDM.
Methods
Patients
Twenty-five asthmatic children (17 boys, 8 girls) aged 6 to 12 yrs were included.
All were characterized by symptoms of asthma, increased total serum IgE, and
specific IgE to HDM (RAST class ³ 3, Pharmacia Diagnostics, Uppsala, Sweden).
Children with other allergies proven by a positive RAST test were excluded in
order to obtain a homogeneous population. All children had a forced expiratory
volume in one second (FEV1) of at least 70% of the predicted value, and increased
bronchial responsiveness (histamine provocation concentration £ 8 mg/ml causing a
fall of 20% or more in FEV1 from baseline value). All children used inhaled
corticosteroids (ICS) as maintenance medication, twice daily 200 or 400 µg, for at
least 4 mo before the study and short-acting ß2-adrenergic drugs when needed.
None of the children used long-acting ß2-adrenergic drugs. Routine standardized
information with regard to reduction of environmental stimuli was given previously
by pediatricians and/or nurses at our outpatient clinic. Acaricides, mattress
encasings and dehumidifiers were not used in the investigated houses. Informed
consent from all children and their parents was obtained, and the study was
approved by the Medical Ethics Committee of our hospital.
Study Design
The same measurements were performed in all children both once in spring (March
to May) and once in autumn (August to November). Children were included either
in the spring or in autumn. To complete the group, children were included during
three consecutive years. Seasonal differences were defined as the autumn value
minus the spring value.
Daytime and nighttime symptoms were recorded in a 3-wk period during regular
treatment with ICS and on the sixth day after withdrawal of ICS. At the end of the
3-wk period, a home and school visit was made to collect house dust from floors
of living rooms and bedrooms and from mattresses. Temperature and relative
humidity were measured in each location to obtain absolute humidity (gram water
vapor per kilogram of dry air). A histamine challenge test was performed and a
blood sample was drawn during ICS use at the outpatient clinic to determine
bronchial responsiveness, the eosinophil count, total IgE, and specific IgE to HDM.
FEV1 during and at the sixth day after withdrawal of ICS was performed at the
outpatient clinic. The circadian PEF amplitude (every 4 h during 24 h, expressed as
highest minus lowest PEF value expressed as a percentage of the day’s mean
value) was obtained at home on the sixth day after withdrawal of ICS.
57Clinical Characteristics
SYMPTOMS: Symptoms of cough, wheeze, dyspnea and phlegm production during
the day and at night were recorded in a diary on a 4-point scale (0: no symptoms,
1: mild, 2: moderate, 3: severe) (6). Daytime and nighttime symptoms were
recorded and added up during the 3-wk period to obtain the total symptom score at
daytime and nighttime during ICS. Symptoms were also recorded during daytime
and nighttime on the sixth day after withdrawal of ICS.
LUNG FUNCTION AND BRONCHIAL RESPONSIVENESS: Short-acting ß2-
adrenergic drugs were withheld 8 h before the measurements. PEF measurements
were performed at home, every 4 h during 24 h, in an upright position with a mini-
Wright peak flow meter to assess the circadian PEF amplitude. The best of three
efforts was used for statistical analysis. FEV1 was measured with a water-sealed
spirometer (Lode BV, Groningen, the Netherlands). At least three reproducible
values (i.e. < 5 percent difference among the recordings) were obtained; the highest
was used in the analysis. Airway histamine challenge tests were performed during
ICS with a gauged DeVilbiss 646 nebulizer (DeVilbiss, Somerset, MA, USA), with
an output of 0.13 ml/min according to the modified method of Cockcroft and
colleagues (7). A 0.9% phosphate-buffered saline solution and doubling histamine
concentrations from 0.03 to 16 mg/ml were inhaled for two minutes during tidal
breathing, with the nose clipped, at 5 min intervals, until FEV1 had fallen by at
least 20% from the initial value. The exact provocation concentration of histamine
that induced a 20% fall in FEV1 (PC20) was assessed by a log-dose response curve.
Laboratory Investigations
Total IgE and specific IgE were quantified using an enzyme immunoassay
procedure (Pharmacia Diagnostics), and expressed in international units (IU) per
milliiter, and Phadebas RAST units (PRU) per milliliter, respectively.
House Dust Mite Allergen Exposure
All dust samples were obtained by the same technician, using a vacuum cleaner
(Phillips type T580, 1100 W). For every location we used a different double-
walled disposable paper bag (8), and a special vacuum cleaner filter for the
mattresses (ALK filter device; surface, 38 cm
2, pore size, 6 µm; ALK, Hfrsholm
Denmark). Dust was collected from the total area of the location in order to obtain
a representative sample. The total amount of fine dust of each floor sample was
measured after filtering with a 355-µm aperture sieve. Each sample was analyzed
for the amount of HDMA (Der p I and Der p II) per gram of fine dust according
to the WHO International standards (9,10). After extraction of the dust samples,
HDMA was analyzed by sandwich immunoassay using monoclonal antibodies (1).
Statistical Analysis
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FEV1 values were expressed as percentage of the predicted value (% pred) (11).
PC20 values were used after logarithmic transformation (base 2), since these reflect
doubling doses and a normalized distribution. In subjects who did not reach a 20%
fall in FEV1 after the maximum exposure of 16 mg/ml histamine (springn=4 ) ,
PC20 was considered to be one doubling doses higher (32 mg/ml). Total IgE and
specific IgE HDM were logarithmically transformed (base 10) to normalize the
distribution. Skewedness of distributions was assessed with a Kolmogorov-Smirnov
test. If a p value < 0.05 was obtained, nonparametric techniques (Spearman’s rho
for correlation, Mann Whitney U test to compare group means) were applied to
analyze the data, values being expressed as median (minimum to maximum).
Otherwise, parametric analyses (Pearson’s r for correlation, Student’s t test for
comparison of groups means) were used and values were expressed in mean ± SD.
Total HDMA exposure to D. pteronyssinus was determined by adding up the
HDMA exposure to Der p I/g and Der p II/g. When the HDMA concentration was
below detection level, the minimum detection concentration (0.01 µg/g for Der pI
and Der p II) was used for calculations. Seasonal differences in clinical parameters
were defined as the autumn value minus the spring value. Multiple regression
analysis was performed to obtain a significant model for the seasonal difference in
PEF amplitude after withdrawal of ICS as the dependent variable with the seasonal
difference in HDMA exposure in the mattress (< -5 µg/g, -5 up to +5 µg/g and >
5µg/g of fine dust) as the independent variable. A p value less than 5% was
considered as statistically significant. All analyses were performed with SPSS/PC+
package, version 4.0 (SPSS Inc, Chicago, IL, USA).
Results
Clinical Characteristics
Clinical characteristics of the children are presented in Table 1. Symptom scores,
FEV1, and PEF amplitude were not significantly different between the spring and
autumn season. Mean PC20 histamine was significantly lower in autumn (p < 0.05)
than in spring. The total number of eosinophils increased significantly during
autumn (p < 0.05). PEF amplitudes, total IgE, and specific IgE to HDM were not
significantly different between the two seasons.
Seasonal Exposure to Exogenous Stimuli
There was a significant seasonal difference in HDMA exposure due to a higher
HDMA exposure in the autumn (Table 1). No significant correlation was found
between the magnitude of HDMA exposure and the level of absolute humidity.
Smoking habits, presence of pets and floor-coverings did not changed during the
study period.
59PEF amplitude after withdrawal of ICS
PEF amplitude after withdrawal of ICS in spring and autumn did not significantly
correlate with the level of HDMA exposure in the same season (Table 2).
However, PEF amplitude correlated significantly and inversely with PC20 in autumn
(Table 2) and positively with daytime symptoms after withdrawal of ICS in the
spring (rho = 0.47; p = 0.01).
Though highest HDMA levels and PEF amplitudes were expected to occur in the
autumn, this was not the case in all children (living roomn=7 ,b e dr o o mn=5 ,
mattress n = 8). Therefore, we calculated whether correlations existed between the
seasonal difference in PEF amplitude (autumn value minus spring value) and
the other clinical variables.
The seasonal difference in PEF amplitude after withdrawal of ICS correlated
significantly and positively with the seasonal difference in total symptom score at
night during ICS (rho = 0.44; p = 0.02), inversely with the seasonal difference in
FEV1 after withdrawal of ICS and positively with the seasonal difference both in
total HDMA exposure and in mattresses (Table 2). Figure 1 shows that children
with a higher seasonal difference in HDMA exposure in the mattresses had higher
seasonal differences in PEF amplitude after withdrawal of ICS. Since not all
children had the highest HDMA exposure level in the autumn, the Figure also
shows negative seasonal differences in HDMA levels and PEF amplitudes.
A multiple regression analysis on the PEF amplitude after withdrawal of ICS
showed a significant explaining model (R
2 = 21.0%, p = 0.02) with the seasonal
difference in HDMA in the mattress as the only significant contributing variable
(Table 3).
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25. Seasonal variations in HDM influences circadian PEF amplitude
TABLE 3 Multiple regression model for the seasonal difference in PEF amplitude after
withdrawal of inhaled corticosteroids (R
2 = 21.0%, p = 0.02)
ß p value
Constant -25.5 0.03
Seasonal difference in
HDMA exposure in the mattress 11.7 0.02
HDMA: house dust mite allergen.
63Figure 1 Seasonal difference (autumn minus spring value) in house dust mite allergen (HDMA)
exposure of Der p I and Der p II (µg/g) in mattress and PEF amplitude after withdrawal of
inhaled corticosteroids (ICS). Seasonal difference in HDMA exposure is divided in 3 categories (<
-5 µg/g, -5 up to +5 µg/g and > 5µg/g of fine dust.
645. Seasonal variations in HDM influences circadian PEF amplitude
Discussion
This study shows that the absolute level of house dust mite (HDM) allergen
exposure is not significantly correlated with the height of the PEF amplitude
neither in autumn nor in spring. An important finding is that a larger seasonal
change in HDM allergen (HDMA) exposure is associated with a larger change in
circadian PEF amplitude. PEF amplitude at a given point in time appears to be
determined by more factors than solely the amount of allergen an individual is
exposed to. Furthermore our data show that an increase in HDMA exposure in the
mattress over seasons enhances an individual’s PEF variability.
Our study stresses the fact that mattresses are quantatively the most important
source for HDM which affects PEF variability particularly (5,12). In a larger group
of HDM-allergic asthmatic children we have previously shown that the occurrence
of environmental tobacco smoke, the presence of pets, and high HDMA exposure
levels together determine the PEF amplitude in one season to a large extent. This
study extends this observation in that changes in exposure levels from the
mattresses between seasons are clinically relevant, since they explained 21% of the
differences in PEF amplitude between seasons.
Studies from different parts of the world found a seasonal variation in HDMA
levels, with highest mean HDMA exposure levels in the autumn months (1,13-16).
Our overall results are in accordance with these observations. However, these
studies and our results indicate that the variation in exposure levels between
seasons can be very small (1,16). Kalra and coworkers observed a statistically
significant difference between the seasons (16), but considered the magnitude of
the intra individual changes between the seasons small and not of clinical
importance. They only measured HDMA concentrations and did not investigate the
effect of changes in allergen exposure levels on clinical variables. Our study points
to the fact that even relatively small changes in HDMA exposure levels are of
clinical relevance for individual patients.
Other studies have emphasized the influence of HDMA exposure levels on clinical
variables with regard to disease severity. Zock and colleagues (17) showed in a
cross-sectional study that a higher diurnal PEF amplitude correlated with higher
HDMA levels collected from carpeted floors. More evidence that HDMA exposure
from mattresses is important comes from HDM reduction studies. Ehnert and
associates (12) compared the effect of treatment of mattresses with an acaricide and
mattress encasements, in allergic asthmatic children. They observed a reduction in
the degree of bronchial responsiveness in the group that was treated with mattress
encasements. Our data support these findings since we show that spontaneous
variations in mattresses HDMA exposure are reflected by changes in circadian PEF
variability.
Our observations confirm the findings of an earlier study in HDM-allergic adult
patients with asthma (1), in which the increase in HDMA exposure level in autumn
65coincided with an increase in bronchial responsiveness. We also found an increase
in bronchial responsiveness together with an increased number of blood eosinophils
in the autumn months, suggesting that the inflammatory process in the lungs is
enhanced in this period of the year. The relationship between increased HDMA
exposure levels on one hand, and increased bronchial responsiveness and increased
blood eosinophils on the other hand is very likely a causal one since all our
children were only allergic to HDM and children with respiratory infections were
excluded. However, we did not find this association for PEF variability. Many
investigators have suggested that PC20 and PEF variability represent both asthma
instability and therefore can be used interchangeably. The discrepancy between
seasonal changes in PC20 which were not reflected in changes in PEF amplitude
indicate that both expressions of bronchial lability provide different information on
the actual disease state as has been shown in earlier studies by other investigators
(18-20).
In summary, we have found measurements of HDMA at a single point of time is
not associated with PEF variability in the same season for all individuals.
Moreover, we found that seasonal differences in PEF amplitude after withdrawal of
ICS correlate significantly and positively with, and are explained to a large extent
by the seasonal difference in HDMA exposure in mattresses. Our results amplify
the general opinion that reduction of HDMA levels in bedrooms of HDM-allergic
children, and especially in mattresses, contributes an essential aspect of the
management of asthma.
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De Lovinfosse et al. recently (Allergy 1994: 49: 64-66) compared levels of mite-
specific IgE (measured by RAST grade (0 - 6) and the level of mite group I
allergen in mattresses (µg/g house dust mite) and found a significant correlation
between both variables (r = 0.57, p = 0.001). Those with a RAST ³ grade 3, had a
77% probability of being exposed to more than 10 µg/g mite allergen; those with
RAST £ grade 2 had a probability of 77% of not being exposed to such high
levels. From these findings, they concluded that serum mite-specific IgE could be
used in routine prediction of mite exposure. We are concerned about the
extrapolation of their findings for clinical and research purposes.
Therefore, we have reviewed data on 25 asthmatic children with an isolated allergy
to house dust mite (HDM), all treated with maintenance therapy of inhaled
corticosteroids. We have collected dust samples from the mattress from September
to November. Median value of Der p I was 6,647 (range: 1,431 - 320,000 ng/g),
median mite-specific IgE was 38 (range: 1.11 - 377 PRU/ml). We found no signi-
ficant correlation between serum mite-specific IgE and Der p I exposure in the
mattresses (rho = 0.07, p = 0.76, see Figure 1). Furthermore, no significant diffe-
rence in HDM exposure was observed for those with RAST < 17.5 PRU/ml (n = 7)
compared with those with RAST > 17.5 PRU/ml (n = 18) (5,422 (4,449 - 32,933)
versus 8,665 (1,431 - 320,000 ng/g Der p I, p = 1.0). Comparable result was found
for those with RAST < 3.5 PRU/ml (n = 2) compared with > 3.5 PRU/ml (n = 23).
As can be seen in Figure 1, there are even cases with high RAST to HDM but low
(< 2,000 ng/g fine dust) Der p I level in their mattress. The results show once
more that group findings and associations can not easily be extrapolated to
individual predictions. Moreover, associations are probably affected by various
factors, (e.g. therapy), as may be the case in our study.
Therefore, we strongly advice clinicians not to use the level of serum specific IgE
as a surrogate of the level of HDM exposure in allergic asthmatic children.
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The present study was set up to investigate whether salmeterol in asthmatic
children already treated with inhaled corticosteroids (ICS) leads to a sustained
bronchodilator effect and decreased bronchial responsiveness, both during the day
and night. Furthermore, we investigated whether cessation of salmeterol leads to a
rebound increase in bronchial responsiveness. Forty asthmatic children (aged 7 to
15 yrs) using ICS participated in a randomized, double-blind, parallel study. They
received either twice daily 50 µg salmeterol xinafoate or placebo. Forced expiratory
volume in one second (FEV1) and provocation concentration of methacholine that
caused a 20% fall in FEV1 (PC20) were measured at 4:00 p.m. and 4:00 a.m. at
baseline and after 16 wk. The same measurements were performed at 4:00 p.m. at
8 h after the first dose, and after 1 and 8 wk. After cessation of the study drug,
FEV1 and PC20 were measured at 12 and 20 h, and after 1 wk. Overall mean FEV1
from 1 to 16 wk of treatment was significantly higher in the salmeterol group than
in the placebo group (difference, 4.9 ± 2.0%, p = 0.01). Evolution in time of FEV1
did not differ significantly between the two groups (p = 0.09). Overall mean PC20
from 1 to 16 wk of treatment was not significantly higher with salmeterol than
with placebo (difference, 0.7 ± 0.4 doubling dose [DD], p = 0.07); evolution in
time of PC20 did not differ significantly between the two groups (p = 0.58). The
increase of PC20 8 h after the start of the study was significantly higher with
salmeterol than with placebo (1.9 ± 0.3 DD versus 0.7 ± 0.3 DD, p < 0.01);
significance disappeared at 1 wk. At 16 wk, the circadian variation (day minus
night value) in FEV1 was significantly smaller with salmeterol than with placebo (-
0.9 ± 0.9% versus 2.2 ± 1.0%, p = 0.03); this was not the case for PC20.N o
rebound worsening of FEV1 or PC20 methacholine was observed after cessation of
salmeterol. Sixteen weeks of treatment with salmeterol given to asthmatic children
on regular ICS leads to a sustained bronchodilator effect and improved circadian
variation in airway diameter. The initial significant decrease in bronchial
responsiveness dropped below significance after 1 wk, and no overall additive
beneficial effect of salmeterol on bronchial responsiveness was present. Finally,
cessation of salmeterol after 4 mo of treatment does not lead to a rebound increase
in bronchial responsiveness in asthmatic children treated with inhaled ICS.
Introduction
Despite maintenance medication with inhaled corticosteroids (ICS), a number of
asthmatic children may have a pronounced circadian variation in airway diameter.
This may cause interrupted sleep and early morning dyspnea, resulting in
diminished concentration and school performance (1). A single inhalation of
salmeterol induces bronchodilation for at least 12 h and may thus specifically
727. Salmeterol added to inhaled corticosteroids
prevent the nocturnal dip in lung function when inhaled in the evening (2).
Salmeterol is also known to provide well-maintained bronchodilation in long-term
treatment (3-8). Moreover, it prevents airway narrowing induced by a number of
bronchoconstricting stimuli (9-12). Therefore salmeterol seems a good choice as
adjuvant therapy when ICS appear to be insufficient to stabilize asthma.
Recently it has been found that long-term monotherapy with salmeterol results in
tolerance to the bronchoprotection against methacholine (13) and exercise (14),
despite well-maintained bronchodilatory potential. Others could not confirm this
observation of tolerance after long-term treatment with salmeterol (15). Further
studies suggest that sudden withdrawal of short-acting ß-agonists may result in
rebound increase in bronchial responsiveness (16,17).
ICS are known to reduce the fall in lung function and bronchial responsiveness and
associated symptoms (18). Since salmeterol is effective for 12 h, it may be used as
an adjunct to ICS when e.g. nocturnal symptoms remain. We therefore investigated
in asthmatic children already treated with ICS whether 16 wk of treatment with
salmeterol leads to a sustained bronchodilator effect and decreased bronchial
responsiveness both during the day and night. Furthermore, we assessed whether
cessation of salmeterol after 4 mo, when added to a regimen of ICS, also leads to a
rebound increase in bronchial responsiveness.
Patients and methods
Subjects
Forty children with a history of allergic asthma (23 boys, 17 girls), aged 7 to 15
yrs, participated in this study. The children were selected from our outpatient
department. All children were characterized by an increased total serum IgE and
specific IgE to one or more common inhalation allergens (RAST ³ 2, Diephuis
Laboratories, the Netherlands), forced expiratory volume in one second (FEV1)a s
percentage of the predicted value ³ 70%, and increased bronchial responsiveness
(histamine provocation concentration < 8 mg/ml (2 min tidal breathing inhalation; 5
min interval) causing a fall of 20% or more in FEV1 from baseline (19). Symptoms
were well-controlled for at least 4 mo before the study with maintenance ICS
(twice daily 200 or 400 µg beclomethasone dipropionate rotadisk) and ß2-adrenergic
drugs if needed (salbutamol rotadisk). Informed consent from all children and their
parents was obtained. The study was approved by the Medical Ethics Committee of
the University Hospital of Groningen.
Study Design
The study had a randomized, double-blind, placebo-controlled, parallel design.
There were three phases: a baseline period (screening and entry-day), regular
treatment (16 wk), and cessation of treatment (1 wk). At the end of the baseline
73period, the subjects were randomly assigned to one of the two groups, using either
a dry powder inhaler (diskhaler) salmeterol xinafoate, 50 µg per inhalation, or a
matched placebo at 8:00 a.m. and 8:00 p.m. First and last inhalations (after 16 wk
of treatment) of the drug were supervised. Tests of FEV1 and provocative
concentration of methacholine that caused a 20% fall in FEV1 (PC20) were
performed at 4:00 p.m. and thereafter at 4:00 a.m. at entry day. During regular
treatment FEV1 and PC20 were performed 8 h after the first inhalation of the first
study medication (4:00 p.m.), after 8 wk of regular treatment (4:00 p.m.) and after
16 wk of regular treatment (4:00 p.m. and therafter at 4:00 a.m.). During cessation
of treatment FEV1 and PC20 were performed 12 and 20 h (8:00 a.m. and 4:00 p.m.)
and 1 wk after the last study medication (4:00 p.m.). Time points of measurement
(8 h after inhalation of the drug) were deliberately chosen since they reflect a more
day-to-day control of the disease than measurements 1 h after inhalation, at the
functional optimum of salmeterol. The time points of measuring bronchial
responsiveness are within the period of action of salmeterol. Patients remained in
hospital during the nocturnal measurements and the measurements on the day
thereafter. Symptoms (wheezing, dyspnea, coughing, and phlegm production) (18)
and rescue medication, during both day and night, were recorded (yes or no) for 1
wk during base-line period, the last wk of regular treatment period, and during
cessation of treatment. Compliance of the study medication was checked after the
study by counting the returned powder disks. The children were allowed to use a
dry powder inhaler (diskhaler) delivering salbutamol with a maximum of 1,600 µg
daily as rescue medication. Rescue medication was stopped for at least 8 h before
the measurements.
Power analysis before the study estimated that 40 participating children were
sufficient to detect 1 doubling dose (DD) improvement in PC20 methacholine.
FEV1 and Methacholine Responsiveness
FEV1 was measured with a water-sealed spirometer (Lode BV, Groningen, the
Netherlands). At least three reproducible values (i.e. < 5% difference between the
recordings) were obtained; the highest was used for analysis.
Bronchial challenge tests were performed with a gauged DeVilbiss 646 nebulizer
(DeVilbiss, Somerset, MA, USA), with an output of 0.13 ml/min (19). A 0.9%
phosphate-buffered saline solution and doubling methacholine-bromide
concentrations ranging from 0.038 to 19.6 mg/ml (equipotent to 0.03 to 16 mg/ml
methacholine chloride) were inhaled for 2 min, with the nose clipped, at 5 min
intervals, until FEV1 had fallen by 20% from baseline FEV1.P C 20 was assessed by
linear interpolation of the last two points of the log concentration response curve.
Short-acting ß2-agonists were withdrawn 8 h before the measurements, ICS were
continued.
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Data Analysis
FEV1 values were expressed as percentage of the predicted value (% pred) (20).
PC20 values were used after logarithmic transformation (base 2). In subjects who
did not reach a 20% fall in FEV1 after the maximum dose methacholine, PC20 was
considered to be one DD higher (39.2 mg/ml).
Distributions of variables with a Gaussian-shaped distribution were summarized by
mean and standard deviation. Precision of estimated means and effects was
presented by standard error of mean (SEM). For variables with a non-Gaussian-
shaped distribution, the median and range (minimum, maximum) were used.
Groups were compared by using the unpaired t test (Gaussian-shaped variables),
the Mann-Whitney U test (non-Gaussian-shaped or ordinal variables), Chi-square
test, or Fisher’s exact test (categorical nominal variables). Treatment effects were
estimated by applying rmANOVA to the relevant outcome variable, with treatment
as between-patient grouping factor, time as within-patient factor, and the baseline
measurement of the outcome variable as a fixed covariate. In a special analysis we
added the interaction of time and treatment to the model to test constancy of the
treatment effect over time, with time either as a factor or a quantitative trend
variable. A p value less than 0.05 was considered to denote statistical significance.
All analyses were performed with the packages SPSS/PC+ and BMDP (module
5V).
Results
Baseline period
One subject in the placebo group did not complete the study because of reasons
unrelated to the study, but was included in the analyses up to his last visit (at 8 wk
of treatment). Characteristics of the subjects in the baseline period were well in
balance between the salmeterol and placebo groups (Table 1), daily dosages of
inhaled corticosteroids were not significantly different between both treatment
groups (p = 0.06). Daytime FEV1 values of the total study group were significantly
higher than at night (93.7 ± 14.3% and 90.3 ± 16.0% respectively, p < 0.01). This
was not found for the PC20 values (geometric mean PC20 day, 1.0 mg/ml; night, 1.2
mg/ml, p = 0.28). Daytime values of FEV1 and PC20 were higher but not
significantly different in those who received 200 µg versus those who received 400
µg beclomethasone twice daily (FEV1: 95.3 ± 13.1% versus 88.4 ± 17.6%, p =
0.21; geometric mean PC20 1.2 mg/ml versus 0.5 mg/ml, p = 0.18). Compliance
was comparable between the two groups.
Regular Treatment
LUNG FUNCTION: Overall mean FEV1 (Figure 1) from 8 h after the first study
medication up to 16 wk of treatment, was significantly higher in the salmeterol
75group than in the placebo group, the difference being 5.4 ± 2.0% (p < 0.01);
difference in time behavior of FEV1 between the two groups, i.e., the course of
FEV1 during the study, was not significant (p = 0.16). Overall mean FEV1 from 1
to 16 wk of treatment was significantly higher in the salmeterol group than in the
placebo group, the difference being 4.9 ± 2.0% (p = 0.01). Difference in time
behavior between the two groups was not significant (p = 0.09).
The increase in FEV1 8 h and 1 wk after the start of the study (Figure 1) was
significantly higher in the salmeterol than in the placebo group (5.7 ± 2.3%
versus -1.4 ± 1.7%, p=0.02 after 8 h, and 4.7 ± 1.7% versus -3.3 ± 2.0%, p = 0.01
after 1 wk). Thereafter, differences between the two groups decreased and became
insignificant (2.9 ± 2.0% versus -0.3 ± 2.5%, p = 0.3 after 8 wk, and 5.8 ± 2.6%
versus 2.2 ± 2.1%, p = 0.3 after 16 wk).
BRONCHIAL RESPONSIVENESS: Overall mean PC20 (Figure 1) from 8 h after
the first study medication, up to 16 wk of treatment, was significantly higher in the
salmeterol group than in the placebo group (0.9 ± 0.4 DD, p = 0.02), when
simultaneously tested over all time points. Overall mean PC20 f r o m1t o1 6w ko f
treatment was not significantly higher in the salmeterol group than in the placebo
group (0.7 ± 0.4 DD, p = 0.07) when simultaneously tested over all but the first
time points. Testing constancy of the treatment effect over time did not reach
significance, neither over all time points (p = 0.32), nor over all but the first time
points (p = 0.58). Using time as a quantitative trend variable (instead of factor)
also did not lead to a significant time by treatment interaction.
The increase in PC20 8 h after the start of the study was significantly higher in the
salmeterol group than in the placebo group (1.9 ± 0.3 DD and 0.7 ± 0.3 DD, p <
0.01). Thereafter, differences in mean PC20 between the two groups became smaller
and lost their statistical significance when tested seperately on each of the three
later time points.
Both the salmeterol and the placebo group showed a significant increase in PC20
from baseline after 1 wk of treatment (salmeterol: 1.7 ± 0.3 DD, p < 0.01, and
placebo: 0.9 ± 0.4 DD, p=0.04). This remained significant in the salmeterol group
(1.2 ± 0.4 DD, p = <0.01 after 8 wk, and 1.1 ± 0.4 DD, p = 0.01 after 16 wk).
This increase was not significant after 8 wk of treatment in the placebo group (0.6
± 0.3 DD, p = 0.11), but it was significant after 16 wk of treatment (0.8 ± 0.4 DD,
p = 0.05).
No significant differences in PC20 between those who received twice daily 200 or
400 µg beclomethasone could be observed within the salmeterol group.
CIRCADIAN VARIATION: Day-night differences in FEV1 at baseline were
comparable in the salmeterol and the placebo groups (2.0 ± 1.3% versus 4.7 ±
1.2%, p = 0.12), but at 16 wk this difference was significantly smaller with
salmeterol than with placebo (-0.9 ± 0.9% versus 2.2 ± 1.0%, p = 0.03) (Figure 2).
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Improvement in nocturnal FEV1 during 16 wk of treatment with salmeterol was not
significantly higher than with placebo (8.7 ± 2.5% versus 4.9 ± 2.1%, p = 0.25).
The day-night differences in PC20 were both at baseline and after 16 wk of
treatment not significantly different between the two study groups (p = 0.8) (Figure
2).
Cessation of Treatment
LUNG FUNCTION, BRONCHIAL RESPONSIVENESS: No significant
differences in FEV1 and PC20 methacholine values could be observed between the
two study groups at 12 h, 20 h and 1 wk after cessation of the study medication
(Figure 3), neither when compared to the placebo nor when compared to baseline
values.
Subjective Aspects
Daytime and nighttime symptoms and the use of rescue medication (Table 2) were
low and not sinificantly different between the salmeterol and placebo group during
the baseline period, treatment period, and after cessation of the study medication.
77TABLE 1 Characteristics of the study subjects by group, means (SD)
ICS + SLM ICS + PLA
No. of patients 20 20
Male/female 11/9 12/8
Age (yrs) 11.4 (2.4) 11.4 (2.8)
Weight (kg) 41.2 (10.6) 39.6 (13)
Height (cm) 149 (15) 147 (18)
ICS 400/800 µg daily 13/7 18/2
Duration of asthma (yrs) 8.9 (2.3) 7.7 (3.0)
Daytime
FEV1 % (pred) 93.6 (12.9) 93.8 (15.9)
FEV1 / VC (%) 81.7 (8.7) 85.2 (9.0)
PEF (l/min) 365 (91) 369 (107)
Log2 PC20 (mg/ml) 0.26 (1.97) -0.25 (2.35)
Geometric mean PC20 (mg/ml) 1.20 0.84
Nighttime
FEV1 (% pred) 91.6 (13.5) 89.0 (18.4)
FEV1 / VC (%) 80.2 (9.7) 82.5 (10.1)
PEF (l/min) 361 (90) 360 (106)
Log2 PC20 (mg/ml) 0.49 (2.65) 0.06 (2.29)
Geometric mean PC20 (mg/ml) 1.41 1.04
ICS: inhaled corticosteroids; SLM: salmeterol; PLA: placebo. 400/800: number receiving
200 µg or 400 µg beclomethasone twice daily.
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9Figure 1 Mean (SEM) change in 4:00 p.m. FEV1 % pred values (upper panel) and mean (SEM)
change in 4:00 p.m. PC20 methacholine doubling doses (DD) values (lower panel) from baseline,
of those who used inhaled corticosteroids with salmeterol (closed circles) and those who used
inhaled corticosteroids with placebo (open circles). *: p < 0.05 between the two groups (t tests).
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Figure 2 Mean (SEM) change in FEV1 % pred values (upper panel) and mean (SEM) change in
PC20 methacholine doubling dose (DD) values (lower panel) from baseline at 4:00 p.m. and 4:00
a.m. during baseline and after 16 wk of treatment of those who used inhaled corticosteroids with
salmeterol (closed circles) and those who used inhaled corticosteroids with placebo (open circles).
*: p < 0.05 for circadian variation between the two study groups at post-treatment period (t test).
81Figure 3 Mean (SEM) change in FEV1 % pred values (upper panel) and mean (SEM) change in
PC20 methacholine doubling dose (DD) values (lower panel) from baseline during wash-out period
(12 h, 20 h and 1 wk after the last study medication) of those who used inhaled corticosteroids
with salmeterol (closed circles) and those who used inhaled corticosteroids with placebo (open
circles).
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Discussion
This study in asthmatic children demonstrates that addition of salmeterol for 16 wk
to maintenance treatment with inhaled corticosteroids (ICS) results in a sustained
bronchodilator effect and a reduced circadian variation in FEV1. Addition of
salmeterol to ICS leads to a direct improvement of PC20 methacholine.
Nevertheless, the mean change in PC20 after its first effect (from 1 to 16 wk of
treatment with salmeterol) was not significantly different from placebo. This
suggests that the combination of salmeterol and ICS does not seem to provide a
clinically relevant supplementary gain with regard to bronchial responsiveness.
Cessation of salmeterol after 4 mo of treatment showed no rebound worsening in
FEV1 or PC20 in this group of asthmatic children treated with ICS.
Several other studies in adults and children describe the maintained bronchodilating
effect of salmeterol during long-term treatment (3-8,13,21,22). In some of these
studies salmeterol has been investigated as monotherapy (8,13); in other studies
part of the population used other anti-asthma medication, including ICS
(3-7,21,22). In our study all children regularly used ICS. Our results show that
salmeterol added to ICS provides a more pronounced bronchodilation than ICS
alone, which effect did not appear to be significantly modified for 4 mo. We found
that the overall mean FEV1 value in the salmeterol group is significantly higher
than in the placebo group. By including and testing a treatment by time interaction
term in the model, a significant decrement of the bronchodilating effect of
salmeterol could not be demonstrated, which is in agreement with d’Alonzo and
colleagues (22) and Pearlman and colleagues (6).
Fitzpatrick and coworkers (23) showed the importance of a well-maintained
nocturnal bronchodilation by salmeterol, as electroencephalography-controlled sleep
quality improved significantly. Furthermore, salmeterol has been proven to reduce
the number of nightly awakenings due to symptoms as well as sleep-related quality
of life (23,24). ICS may also reduce nocturnal airway obstruction (25,26) along
with reduction in diurnal PEF variation (3,4,6,21,22,27,28). Since salmeterol is
effective for 12 h, it might also be used as an adjunct to ICS when nocturnal
symptoms remain. Our results show for the first time that salmeterol exerts a
beneficial effect, even in children with well-controlled asthma, both on daytime
FEV1, and on the circadian variation in FEV1 when given on top of ICS. This
indicates that salmeterol, in the long term, provides a more pronounced
bronchodilating effect than a regimen with an ICS alone. The children included in
this study, however, had a small circadian variation in lung function with values in
the normal range; therefore, the opportunity to improve with salmeterol was
limited. The clinical relevance of this study is that even in this group of children a
sustained bronchodilator effect of salmeterol can be shown. However, salmeterol
would not be the first choice of bronchodilator at present for this group of
83asthmatic children.
We have observed an increase in PC20 during the 2 d the patients stayed in hospital
in both the salmeterol and the placebo group. This improvement is most likely a
consequence of staying in an allergen-free environment (29) and has been observed
during earlier studies on nocturnal asthma (19,26). We found an increase in PC20 of
almost one doubling dose during 16 wk of placebo inhalation, suggestive for an
increased compliance with ICS. This shows once more the need for placebo-
controlled investigations, when studying bronchodilating and bronchoprotective
effects of drugs.
Wempe and coworkers (26) compared the effects of budesonide and bambuterol
and found that both drugs improved bronchial responsiveness during the day and
night. However, the effect of budesonide was stronger than that of the long-acting
bronchodilator. We show in asthmatic children with only limited airway obstruction
during both day and night, that salmeterol does provide limited improvement in
FEV1, most likely due to a ceiling effect. Even though they had limited airway
obstruction and a small circadian variation in FEV1, the children had moderate to
severe bronchial responsiveness, which did not improve during the day or overnight
when salmeterol was added to ICS. The latter lack of improvement cannot,
however, be explained by a ceiling effect, since there was still enough room for
improvement in PC20.
Our patients were at the start of the study well controlled, with a mean FEV1 >
93% of the predicted value. This seems to be the explanation for the absence of
improvement in subjective aspects after addition of salmeterol to maintenance
therapy with ICS.
Some studies in adults (13,14) and in children (8) with asthma have suggested that
regular treatment with long-acting ß2-agonists may lead to tolerance to its
protective effects against bronchoconstrictor stimuli, such as methacholine (8,13)
and exercise (14). Patients in these studies did not use ICS. In our study we
observed that the mean difference of PC20 between the group receiving salmeterol
and the control group decreased over three consecutive time intervals during 16 wk
of treatment. Although this may easily happen by chance (two sided p = 0.25), it is
not inconsistent with the phenomenon of tolerance. A more formal analysis for
testing the treatment by time interaction did not yield any significance. Hence, this
study, like others (15), did not show tolerance to methacholine provocation. This
study was not designed to study this phenomenon, neither by its measurement
scheme nor by its sample size.
A small rebound effect in bronchial responsiveness has been observed after
cessation of treatment with short-acting ß2-agonists (16,17). Although the clinical
relevance of this finding is dubious, it may be possible that long-term treatment
with long-acting ß2-agonists induces a more pronounced rebound effect. We did not
observe a rebound effect at 12 and 20 h or 1 wk after cessation of salmeterol with
regard to bronchodilation and bronchial responsiveness. This confirms the results of
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others who did not observe a rebound increase in bronchial responsiveness after 5 d
up to 14.5 d after withdrawal of salmeterol (8,13,15,30,31).
We conclude that 16 wk of treatment with salmeterol in asthmatic children treated
with maintenance therapy with ICS leads to a sustained bronchodilator effect
during the day and improved circadian variation in airway diameter. The initial
significant decrease in bronchial responsiveness disappeared, however, after 1 wk.
Salmeterol has no additive beneficial effect on bronchial responsiveness, as no
significant difference in PC20 methacholine or reduction in circadian variation of
PC20 methacholine was observed from 1 wk up to 16 wk of treatment. Finally,
cessation of salmeterol after 4 mo of treatment does not lead to a rebound increase
in bronchial responsiveness in asthmatic children treated with ICS.
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Abstract
Though nocturnal asthma is frequently present in asthmatic children despite
treatment with inhaled corticosteroids (ICS), there is little known on the role of
inflammation in this respect. Neither is known whether the long-acting ß2-agonist
salmeterol may improve nocturnal asthma by way of reducing inflammation. We
investigated daytime and nighttime inflammatory parameters in healthy children
and compared baseline values with allergic asthmatic children already treated with
ICS. Moreover, we assessed whether differences in inflammation between healthy
and asthmatic children are associated with lung function parameters and whether
long-term treatment with salmeterol influenced inflammatory parameters in
asthmatic children. Ten healthy and 40 asthmatic children using ICS participated
(aged 7 to 15 yrs). At baseline a blood sample was taken at 4:00 p.m. and 4:00
a.m. to analyze total number of leucocytes, lymphocytes, eosinophils, ECP, EDN,
and lymphocyte subsets and activation markers (CD3, CD4, CD8, CD4/CD25,
CD4/45Ro, CD4/HLAdr and CD8/CD28). At 4:00 p.m. and 4:00 a.m. asthmatic
children performed a forced expiratory volume in one second (FEV1); the day
before baseline a 24 h peak expiratory flow (PEF) amplitude was measured
(highest minus lowest value expressed as a percentage of the day’s mean value).
Asthmatic children enrolled in a randomized, double-blind, parallel study, receiving
either twice daily 50 µg salmeterol xinafoate or placebo during 16 wk. At 4:00
p.m., asthmatic children had significantly higher values of leucocytes, lymphocytes,
eosinophils, ECP, EDN, CD3+, CD4+, CD8+, CD4/CD45Ro+, and CD4/HLAdr+
cells than healthy children, this was also true for 4:00 a.m. values of ECP and
EDN. ECP and EDN at 4:00 p.m. and 4:00 a.m. correlated significantly and
positively with PEF amplitude (rho > 0.32; p < 0.05). At daytime CD3+, CD4+,
CD8+, and CD45Ro+ correlated significantly and positively with FEV1 % predicted
(rho > 0.27; p < 0.05). Long-term treatment of salmeterol did not normalize
inflammatory parameters. In conclusion: despite treatment with ICS, asthmatic
children do have ongoing eosinophilic activation at day and night, and lymphocytic
activation in daytime. Whereas a higher eosinophilic activation was related with a
larger PEF variability, lymphocytic activation was not. The latter was, however,
moderately associated with the level of airways obstruction (FEV1). Salmeterol did
not significantly improve inflammatory parameters in peripheral blood in allergic
asthmatic children treated with ICS.
Introduction
Asthma is characterized pathologically by the presence of inflammation in the
bronchial mucosa, with an influx and activation of eosinophils, lymphocytes and
mastcells (1). Current guidelines recommend to institute regular use of anti-
89inflammatory drugs in asthma when daily symptoms occur in order to suppress the
inflammatory process, whereas monotherapy with short-acting or long-acting ß2-
agonists are regarded to be unsafe. Systemic side effects in the long-term
management of the disease are usually observed only when daily doses of > 800 µg
of inhaled corticosteroids (ICS) are used (2). Notwithstanding their proven
effectiveness, clinical practice suggests that some children remain symptomatic
despite the use of ICS (3,4). Therefore supplemental therapy may be necessary.
In severe symptomatic asthma an enhanced circadian variation in peak expiratory
flow (PEF) is generally present, which has been associated with an increase in cell
number and activation (5). A study in asthmatic adults showed that additional use
of salmeterol provided a better symptomatic and lung functional benefit than
doubling the dose of ICS (6). This beneficial effect may be largely due to the
bronchodilator properties of the long-acting ß2-agonist, yet some in vitro and in
vivo studies suggest that an anti-inflammatory effect may play a role as well. For
instance Di Lorenzo and coworkers (7) found a reduction of serum eosinophilic
cationic protein (ECP) after 1 wk of treatment with salmeterol in mild asthmatics,
as has been shown to occur with ICS as well (8). However, Gardiner and
coworkers (9) could not show that 8 wk of treatment with salmeterol improved
inflammatory parameters like T-cell activation and tryptase in bronchoalveolar
lavage of asthmatics individuals who were already treated with ICS. However, this
may well be due to the fact that healthy and asthmatic individuals had comparable
values, thus improvement with salmeterol might not have been expected to occur.
The study found a significant difference in the number of eosinophils and epithelial
cells between healthy and asthmatic individuals, but again no effect of salmeterol
was found. So far conflicting results with respect to anti-inflammatory properties of
salmeterol have been presented.
Clinical effects of drugs are usually assessed by measuring symptoms, PEF
(variability), forced expiratory volume in one second (FEV1) and bronchial
responsiveness. Improvement in these indices may, however, reflect different routes
by which the improvement occurs. For instance the level of FEV1 is determined by
airway wall oedema, subepithelial fibrosis, and smooth muscle contraction, and
hence both acute and chronic processes in the airway wall. In contrast, PEF
variability (and not PEF level) may be considered to reflect to a large extent acute
inflammatory changes in the airway wall. We therefore set out to assess the
relationship between inflammatory parameters and these worldwide used indices of
clinical outcome.We have been investigating allergic asthmatic children treated
with ICS. A sustained bronchodilator effect and a reduced circadian variation in
lung function occurred in these children after 16 wk of treatment with salmeterol
(50µg twice daily) when compared with placebo. Addition of salmeterol did not
lead to a clinically relevant supplementary gain with regard to bronchial
responsiveness (10). In this paper we present the results of the same study with
regard to daytime and nighttime changes in inflammatory parameters. We
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compared our baseline values with results in healthy children. Finally we
investigated whether the observed differences in inflammation between healthy and
asthmatic children were associated with abnormalities in spirometry, PEF
variability and bronchial responsiveness. We specifically focused on changes of
eosinophils and lymphocytes.
Patients and methods
Subjects
Ten healthy controls (3 boys, 7 girls), aged 7 to 15 yrs participated. The healthy
volunteers had no history of allergic and respiratory disease. They were
characterized by total serum IgE in the normal range (11) and specific IgE to one
or more common inhalation allergens (RAST class < 2, Pharmacia Diagnostics,
Uppsala, Sweden), FEV1 of at least 90% of the predicted value, and no increased
bronchial responsiveness (histamine provocation concentration > 8 mg/ml [2 min
tidal breathing, 5-min interval] causing a fall of 20% or more in FEV1 from
baseline). Forty children with a history of allergic asthma (23 boys, 17 girls), aged
7 to 15 yrs, participated. The asthmatic children were selected from our outpatient
department. All were characterized by an increased total serum IgE and specific
IgE to one or more common inhalation allergens (RAST ³ 2, Pharmacia
Diagnostics), FEV1 of at least 70% of the predicted value, and increased bronchial
responsiveness (histamine provocation concentration < 8 mg/ml [2 min tidal
breathing inhalation, 5-min interval] causing a fall of 20% or more in FEV1 from
baseline). Symptoms were well-controlled for at least 4 mo before the study with
maintenance ICS (twice daily 200 or 400 µg beclomethasone dipropionate rotadisk)
and ß2-adrenergic drug if needed (salbutamol rotadisk). None of the children used
long-acting ß2-adrenergic drugs before the start of the study.
Informed consent from all children and their parents was obtained. The study was
approved by the Medical Ethics Committee of the University Hospital of
Groningen.
Study Design
There was a baseline period (screening and baseline day) for all participating
children. At the baseline day a blood sample was taken from all children at
daytime (4:00 p.m.) and nighttime (4:00 a.m.) to collect inflammatory parameters
in peripheral blood. The healthy children performed spirometry at daytime and the
asthmatic children performed spirometry and a methacholine challenge test at
daytime and at nighttime. The circadian PEF amplitude (highest minus lowest PEF
value expressed as percentage of the day’s mean value) was obtained at home by
all subjects before the baseline day. After the baseline characterization, asthmatic
children enrolled the long-term intervention study which had a randomized, double
blind, placebo controlled, parallel design which was published earlier (10). They
91were randomly assigned to one of the two groups, using either a dry powder
inhaler (diskhaler) salmeterol xinafoate, 50 µg per inhalation (ICS + SLM group),
or a matched placebo (ICS + PL group) at 8:00 a.m. and 8:00 p.m. First and last
inhalations (after 16 wk of treatment) of the drug were supervised. During the
long-term intervention there were regular clinical visits and telephone contacts for
control of their asthma and adverse events (at 1, 4, 8, and 12 wk). After 16 wk of
intervention (post-treatment period) a blood sample was taken from the asthmatic
children and they performed spirometry and a methacholine challenge test at
daytime and nighttime as well. The PEF amplitude was obtained at home one day
before the hospital visit.
All children remained in hospital during the nocturnal measurements. Compliance
of the study medication was checked after the study by counting the returned
powder disks. The asthmatic children were allowed to use a dry powder inhaler
(diskhaler) delivering salbutamol with a maximum of 1,600 µg daily as rescue
medication. Rescue medication was stopped for at least 8 h before the
measurements.
Processing of Blood
Total IgE and specific IgE were quantified using an enzyme immunoassay
procedure (Pharmacia Diagnostics), and expressed in international units (IU)/ml,
and Phadebas RAST units (PRU)/ml, respectively. Total leucocyte numbers in
EDTA-anticoagulated blood were counted in a Coulter Counter (Model S-plus VI;
Coulter electronics, Hialeah, USA). Viability was assesses by cellular exclusion of
trypan blue. Cell differentiation was assessed on two slides after staining of blood
smears with May-Grünwald-Giemsa. The average of 200 cell counts was taken for
analysis.
ECP and eosinophil derived neurotoxin (EDN) were measured in serum obtained
after coagulation of the blood for1ha troom temperature. The supernatant was
centrifuged twice for 10 min at 2000 g and stored at -80°C until analysis.
Determination was performed by double antibody radioimmunoassays (Pharmacia
Diagnostics AB, Uppsala, Sweden), as described previously (12,13). The detection
level in both assays was 0.1 ng/ml.
Lymphocytes Markers
Lymphocyte subsets and activation state were analyzed by flowcytometry using
double staining procedures, with a Facs 440 (Becton-Dickinson, Mountain View,
CA, USA) equipped with an Argon laser and interfaced with a Hewlett-Packard
Consort 30 computer as published previously (5). Cells were incubated with
appropriate dilutions of mouse monoclonal antibodies (moabs, Becton-Dickinson,
Mountain View, CA, USA) conjugated with a fluorochrome (fluorescein
isothiocyanate [FITC] or phycoerythrin [PE] against CD3 (Leu-4, T-cells), CD4
(Leu 3a, T-helper/inducer cells), CD8 (Leu-2a, T-suppressor/cytotoxic cells). CD25
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(a-chain interleukin 2 receptor), HLA-dr and UCHL (CD45Ro) were used in
combination with anti-CD4 as indices of CD4
+ lymphocyte activation. CD28
(adhesion antigen presenting cell) was determed on CD8
+ cells. FITC and PE
conjugated mouse immunoglobulins of matched isotypes (IgG1, IgG2a ) were used
as negative controls. The percentage of positive cells expressing the surface marker
was assessed.
Blood lymphocytes and monocytes were separately gated according to their
forward and sideward scatter, after verifying the purity using CD45 (Hle-1) and
CD14 (Leu-m3) antibodies. EDTA-blood (100 µl) was fixed with 0.05%
formaldehyde for 10 min at 22°C and centrifugated at 900 g for 2 min, then
incubated for 15 min at 22°C with the appropriate dilutions of moabs supplemented
with 10% AB serum. After lysis of red blood cells with lysing solution (155
mmol/l NH4CL, 10 mmol/l KCl, NaAz 0.02%) the cells were washed, resuspended
with PBS/BSA 0.5% and allowed to regenerate during 30 min at 22°C. A
minimum of 20,000 events were collected for each sample. Analysis was
performed using software (Lysis; Becton-Dickinson).
PEF Amplitude, FEV1 and Methacholine Responsiveness
Short-acting ß2-adrenergic drugs were withheld 8 h before the measurements. PEF
measurements were performed every 4 h during 24 h in an upright position with a
mini-Wright peak flow meter to calculate the circadian PEF amplitude. The best of
three efforts was used for statistical analysis. FEV1 was measured with a water-
sealed spirometer (Lode BV, Groningen, the Netherlands). At least three
reproducible values (i.e. < 5% difference between the recordings) were obtained;
the highest was used for analysis.
Methacholine challenge tests were performed with a gauged DeVilbiss 646
nebulizer (DeVilbiss, Somerset, MA, USA), with an output of 0.13 ml/min
according to the modified method of Cockcroft and coworkers (14). A 0.9%
phosphate-buffered saline solution and doubling methacholine-bromide
concentrations ranging from 0.038 to 19.6 mg/ml (equipotent to 0.03 to 16 mg/ml
methacholine chloride) were inhaled for 2 min, with the nose clipped, at 5-min
intervals, until FEV1 had fallen by at least 20% from baseline FEV1. The exact
provocation concentration of methacholine that induced a 20% fall in FEV1 (PC20)
was assessed by linear interpolation of the last two points of the log concentration
response curve.
Data Analysis
Lymphocyte cell subsets are expressed as absolute number obtained by multiplying
the percentage of positive cells with the total number of lymphocytes. Circadian
variation was defined as daytime value minus nighttime value. FEV1 values were
expressed as percentage of the predicted value (% pred) (15). PC20 values were
used after logarithmic transformation (base 2), since these reflect doubling doses
93and have a Gaussian-shaped distribution. In subjects who did not reach a 20% fall
in FEV1 after the maximum dose of 19.6 mg/ml methacholine (baseline nighttime n
=2 , posttreatment daytime n =2 , nighttimen=2 )P C 20 was considered to be one
doubling doses higher (39.2 mg/ml).
Distributions of variables with a Gaussian-shaped distribution were summarized by
means and standard deviations (SD). For variables with a non-Gaussian-shaped
distribution the median and range (minimum, maximum) were used. Groups were
compared by using the unpaired t test (Gaussian-shaped variables), the Mann-
Whitney U test (non-Gaussian-shaped or ordinal variables). Repeated measures
analysis of variance (rmANOVA) was performed to compare the rhythm of the
PEF values. Spearman’s rho was obtained for correlations between lung function
and inflammatory parameters. This was only performed if parameters differed
significantly between healthy and asthmatic individuals. A p value less than 0.05
was considered to denote statistical significance. RmANOVA was performed with
BMDP (module 5V), statistical package. All other analyses were performed with
the SPSS/PC+ statistical software package.
Results
Baseline Period
One asthmatic subject in the placebo group did not complete the study because of
reasons unrelated to the study, and was included in the analysis at the baseline-
period.
The mean duration of having asthma was 8.3 yrs (SD 2.7 yrs). Baseline
characteristics of the healthy and asthmatic children are shown in Table 1. Total
IgE was significantly lower in the healthy group compared to the asthmatic
children. PEF amplitude in the healthy subjects was significantly lower than in the
asthmatic subjects, but the rhythm during 24 h was comparable (p = 0.33). FEV1
values were not significantly different between the two groups. Daytime FEV1
values of the asthmatic children were significantly higher than at nighttime (Table
1), this was not found for PC20 values. Daytime values of FEV1 and PC20 were
higher, but not significantly different in those who received 200 µg versus those
who received 400 µg beclomethasone twice daily (FEV1: 95.3 (13.1)% versus 88.4
(17.6)%, p = 0.21; geometric mean PC20 1.2 mg/ml versus 0.5 mg/ml, p = 0.18).
Baseline characteristics of the asthmatic children and daily dosages of ICS were
well in balance between the salmeterol and placebo groups (Table 1). Compliance
was comparable between both treatment groups.
Healthy Versus Asthmatic Children
At daytime, healthy children had significantly lower values in the number of
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leucocytes, lymphocytes, eosinophils, CD3+, CD4+, CD8+, CD45Ro+, and
CD4/HLAdr+ lymphocytes compared to asthmatics. The same was true for serum
ECP and EDN levels (Table 2 and 3).
At nighttime, healthy children had significantly lower numbers of leucocytes,
lymphocytes, and eosinophils, as well as lower ECP and EDN levels than asthmatic
children (Table 2). Lymphocyte subsets were not significantly different in healthy
and asthmatic children (Table 3).
Healthy as well as asthmatic children had a significantly lower number of total
lymphocytes and EDN at daytime than at nighttime. Total number of eosinophils
was significantly lower at daytime than at nighttime in healthy children, but not in
asthmatic children (Table 2). Healthy and asthmatic children had significantly
lower number of CD3+, CD4+, CD8+, CD4/CD25+, CD45Ro+, and CD8/CD28+
cells in daytime compared with nighttime values. For CD4/HLAdr+ cells this was
only found in healthy children (Table 3). Circadian variations in numbers of
leucocytes, lymphocytes and their subsets, and eosinophils, and the levels of ECP
and EDN were not significantly different between the healthy and the asthmatic
children.
Relationship of Inflammatory Parameters with Lung Function in Asthmatic
Children
ECP and EDN correlated significantly and positively with PEF amplitude at
daytime and nighttime (rho > 0.32; p < 0.05). At daytime, CD3+, CD4+, CD8+,
and CD45Ro+ cells correlated significantly and positively with FEV1 % pred (rho
> 0.27; p < 0.05). None of the inflammatory parameters correlated with the
circadian variation in FEV1. At daytime, the total number of CD4/HLAdr+ cells,
and at nighttime the total number of lymphocytes correlated significantly and
positively with PC20 (rho > 0.28; p< 0.05). See Table 4.
Changes after Treatment with Salmeterol
The change in circadian variation with 16 wk of treatment of salmeterol compared
to placebo was not significantly different for all inflammatory parameters
measured. This was also true for absolute daytime values (Table 5 and 6).
At night, we observed significant differences due to treatment between the group
that received salmeterol and the placebo group with regard to changes in the
number of lymphocytes, CD8+ and CD8/CD28+ cells (number of lymphocytes in
the ICS + SLM group: -0.3 [-1.5 - 0.6] versus ICS + PL group: 0.1 [-1.3 - 1.5], p
= 0.04; number of CD8+ cells in the ICS + SLM group: -0.1 [-0.5 - 0.2] versus
ICS + PL group: 0.0 [-0.3 - 0.4], p = 0.03; number of CD8/CD28+ cells in the ICS
+ SLM group: -0.1 [-0.3 - 0.2] versus ICS + PL group: 0.0 [-0.2 - 0.5], p = 0.05).
See Table 5 and 6.
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7TABLE 3 Absolute number of lymphocyte subset positive cells (10
9/l) at daytime and
nighttime in healthy (n = 10) and asthmatic (n = 40) children
Healthy Asthma
Daytime
CD3 1.4 (1.1 - 1.9) * 1.9 (0.6 - 4.7)
CD4 0.8 (0.6 - 1.2) * 1.2 (0.3 - 2.8)
CD8 0.5 (0.3 - 1.0) * 0.8 (0.3 - 1.7)
CD4/CD25 0.1 (0.0 - 0.1) 0.1 (0.0 - 0.1)
CD45Ro 0.3 (0.2 - 0.6) * 0.4 (0.1 - 0.5)
CD4/HLAdr 0.0 (0.0 - 0.0) * 0.0 (0.0 - 0.1)
CD8/CD28 0.4 (0.2 - 0.7) 0.5 (0.2 - 1.1)
Nighttime
CD3 2.0 (1.5 - 3.0)# 2.5 (0.9 - 3.6)#
CD4 1.1 (0.8 - 1.9)# 1.4 (0.5 - 2.4)#
CD8 0.8 (0.6 - 1.1)# 1.0 (0.4 - 1.7)#
CD4/CD25 0.1 (0.1 - 0.2)# 0.1 (0.0 - 0.2)##
CD45Ro 0.3 (0.3 - 0.8)# 0.4 (0.1 - 0.7)#
CD4/HLAdr 0.1 (0.0 - 0.1)# 0.1 (0.0 - 0.1)
CD8/CD28 0.6 (0.4 - 1.0)# 0.7 (0.2 - 1.2)##
Values are expressed as median (minimum - range), statistics differences with Mann-
Whitney U tests. *: p < 0.05 healthy versus asthmatic children. #: p < 0.05, ##:p£
0.001, daytime versus nighttime.
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1Discussion
This study shows that asthmatic children with high doses of inhaled corticosteroids (ICS)
still have ongoing inflammation, since we found higher serum ECP and EDN levels both
day and night as well as higher numbers of peripheral blood lymphocytes and especially
activated CD4+ lymphocytes in daytime than in healthy children. PEF variability was
positively and significantly related with higher ECP and EDN levels both in daytime and
nighttime, whereas FEV1 was significantly associated with activated lymphocytes in
daytime, as was bronchial responsiveness. Finally, 16 wk of salmeterol treatment did not
change the above mentioned inflammatory parameters to the normal range.
The present study is the first of which we are aware that documents circadian
inflammatory parameters in peripheral blood in asthmatic children. There are only a few
studies on inflammatory parameters in peripheral blood in children. Three weeks after
allergen avoidance in a high altitude climate, a significant reduction in CD25+/CD4+ cells
in peripheral blood of asthmatic children was found, combined with a reduction in the
number of eosinophils (16). Gemou and coworkers (17) who compared the absolute
numbers of CD4+ and CD8+ T-cells in peripheral blood between asthmatic allergic
children and non-asthmatic-allergic children and found no significant difference between
both groups, whereas the absolute number of eosinophils of asthmatic children was
elevated compared to the non-asthmatic children. They did not compare their data with
healthy children. We found a difference in inflammatory parameters in peripheral blood
between healthy and asthmatic children treated with ICS. Variations in T-lymphocytes in
asthmatic patients are related to the disease severity and may therefore differ from healthy
subjects. One study showed the numbers of activated T-cells to be related to the severity
of asthma, as measured by impairment of FEV1, and increased methacholine bronchial
responsiveness (18). This is in contrast with Gerblich and coworkers who concluded that
T-cell subsets in peripheral blood of asymptomatic adult asthmatics did not differ from
healthy subjects (19). Since our patients were still symptomatic and mildly
hyperresponsive and furthermore were much younger in age, this might explain the
different findings. All these studies were performed at daytime. Although we found some
differences in inflammatory parameters between daytime and nighttime values of
asthmatic versus healthy children, the day-night variation was not different. This may be
due to treatment with ICS.
A drawback of our study is that we assessed our inflammatory parameters in peripheral
blood. Peripheral blood contains only 2% of all lymphocytes and may not contain highly
differentiated antigen-specific T-cells, which are specifically localized in inflammatory
tissues. It thus only partly reflects the inflammatory process in the airway walls.
However, bronchoalveolar lavage in children is not easily done, nor acceptable for the
child without sedation. We therefore first started to look at peripheral blood inflammatory
parameters. Lymphocytes are recruited into peripheral blood under allergen challenge
conditions in sensitized asthmatic children (20). Virchow and coworkers (21) found that
after segmental allergen challenge the number of neutrophils and activated CD4+ cells
(CD25+) increased significantly in peripheral blood, but no change in eosinophils and
other leucocytes or lymphocyte subsets. This type of challenge does, however, reflect an
acute event after a supraphysiologic dose of allergen and may not represent the ongoing
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chronic inflammatory process we have been investigating in our children. A study of
Oosterhoff and coworkers (5), containing patients with increased circadian PEF
variability, found that a higher number of HLA-dr/CD4+ cells in lavage fluid was
associated with increasing circadian PEF rhythm, but this was not present with peripheral
blood values. This finding is compatible with our observations.
We assessed associations between the inflammatory parameters that were significantly
different between healthy and asthmatic children and the critical outcome measures in
clinical studies, i.e. FEV1, PEF amplitude and bronchial responsiveness. We found,
although with a rather small rho value (explaining about 10% of the variation), that a
larger PEF variability was related to higher level of eosinophilic activation. The level of
FEV1, and to a smaller extent bronchial responsiveness was, however, not associated with
eosinophilic activation but with lymphocyte activation. The interpretation of the findings
is difficult given their finding in peripheral blood (see above). It is attractive to speculate
that acute eosinophilic activation (both day and night) is important to the acute variability
in airway diameter, i.e. PEF variability, whereas this has not such a large effect on the
level of fixed airway obstruction. This increased eosinophilic activation has already been
found to occur 3 h after allergen challenge (22). In contrast, the reduction in the absolute
level of FEV1 is more likely due to both acute and chronic ongoing inflammatory
processes in the airway wall. A higher activation of peripheral blood lymphocytes has
been previously found after the late allergic reaction upon allergen challenge (21),
supporting the slower onset of lymphocyte activation than eosinophilic activation. We
observed a higher FEV1 to be associated with higher chronic lymphocyte activation, as
evidenced by increased expression of CD45Ro, combined with a somewhat more acute
activation parameter HLA-dr. We would have expected a negative correlation if the
hypothesis that chronic activation leads to irreversible damage. However, it has been
mentioned before that lymphocyte activation does not concur between different
compartments, such as peripheral blood, bronchalveolar lavage fluid and airway wall
tissue (23,24). Thus, biopsy studies have to show whether the number of CD4/CD45Ro+
cells are higher in airway wall biopsies of asthmatic individuals with lower FEV1 values.
ß-Agonists have effects on a wide variety of cell types in the airways and on
inflammatory cells. Little is known about the effect in vivo of salmeterol on inflammatory
parameters. Gardiner and coworkers (9) studied in asthmatic adults receiving regular ICS
therapy the effect of salmeterol on lavage-indices, but did not find a significant change in
percentage CD4+, CD8+ or proportion of HLA-dr expressing lymphocytes after 8 wk of
salmeterol treatment. Taylor and coworkers (25) concluded that salmeterol and salbutamol
did not inhibit mediator release from pulmonary inflammatory cells, whereas Baker and
coworkers (26) found that salmeterol inhibits the release of thromboxane B2 from both
airway macrophages and freshly isolated blood monocytes in vitro. ß-Agonists have little
or no effect on the chronic inflammatory response that underlies airway
hyperresponsiveness and chronic asthma. This is most clearly demonstrated by biopsy
studies showing that regular treatment with ß-agonists, including salmeterol, fails to
resolve the inflammatory process, as judged by inflammatory indices in bronchial biopsies
or bronchoalveolar lavage (9,27,28). We found a significant reduction of nighttime total
lymphocytes as also found with short-acting ß2-agonists (29) during salmeterol treatment,
but the clinical relevance is unknown. Our data support previous findings in that inhaled
103ß2-agonists do not suppress the underlying inflammation of asthma in the way steroids do,
and yet they may control the symptoms of asthma.
In summary our data show that asthmatic children, despite their treatment with ICS, do
have ongoing eosinophilic activation at day and night and lymphocytic activation in
daytime. Eosinophilic activation was moderately related to the variability in airway
diameter, whereas this was not the case for lymphocytic activation. Despite clinical
improvement with salmeterol treatment, we could not find any improvement in
inflammatory parameters in daytime, even though there was room for improvement given
the observed differences in inflammatory parameters between healthy and asthmatic
children treated with ICS.
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106CHAPTER 9
SUMMARY, CONCLUSIONS AND RECOMMENDATIONSNocturnal respiratory symptoms are common in children with asthma. This is
generally attributed to increased airway obstruction and hyperresponsiveness at
night. A circadian variation in airway diameter has been described both in healthy
children and in children with asthma. In healthy children this 24 hours variation is
small, and it is enhanced in many asthmatic patients, especially when in a unstable
phase of the disease. The best lung function values occur during the daytime, while
trough values are generally measured at the end of the night. This causes patients
and their parents to wake up with negative consequences for school performance
and disruption of family life.
Nocturnal complaints of asthma have been recognized for a long time. An
increased nocturnal airflow limitation has already been described in the fourth
century AD. In the forties and fifties of this century, research into determinants of
increased airway obstruction began, to which the Groningen group contributed. Up
to now, research on the phenomenon of nocturnal airflow limitation has largely
focussed on endogenous rhythms, such as the contribution of variations of the
autonomic nervous system, variations in cortisol secretion, or associations of
variations in inflammatory variables and the nocturnal fall in lung function.
Although parts of the puzzle have been elucidated, other parts are still unknown.
During earlier studies in allergic asthmatic children we have observed that the
nocturnal airflow limitation as measured at home improved during a short stay in
hospital. This led to the hypothesis that next to endogenous factors, exogenous
(environmental) triggers such as allergens and tobacco smoke were also able to
modulate the circadian variation in airflow limitation.
This thesis aimed to give more insight in, on one hand, the epidemiology of
nocturnal respiratory symptoms in children with asthma who are regularly
controlled on an outpatient clinic for asthmatic children. On the other hand, it tries
to answer the question whether environmental triggers are of importance for the
magnitude of the circadian variation in airflow limitation. As it has been suggested
that the inflammatory process in the lungs is more active during the night,
environmental triggers, such as inhaled allergens, could activate this inflammatory
process. Several studies suggested that the inflammatory process is more severe
during the night in patients with nocturnal airflow limitation. These studies show
an increase of inflammatory cells and mediators in blood and urine during the night
(1-4). More direct evidence is shown by an increase in inflammatory cells and
activation markers in bronchoalveolar lavage fluid obtained during the night (5,6).
Anti-inflammatory drugs such as inhaled corticosteroids (ICS) are known to reduce
the degree of inflammation and reduce 24 hours variation in peak expiratory flow
(PEF) (7,8).
Long-acting ß2-agonists have proven to be especially beneficial to overcome the
nocturnal fall in lung function in asthmatic patients (9). In the earliest studies it has
been suggested that they possessed also anti-inflammatory properties, since a single
inhalation prevented not only the early asthmatic reaction after allergen inhalation,
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but also the late asthmatic reaction (10). Therefore, we studied the effect of 16
weeks treatment with the long-acting ß2-agonist salmeterol on daytime and
nighttime lung function, bronchial responsiveness and inflammatory variables in
peripheral blood of allergic children treated with ICS.
Chapter 1.1 contains a literature study on the epidemiology of nocturnal symptoms
of asthma in different populations. Furthermore, the literature on mechanisms that
may modulate the circadian variation in lung function is discussed. It is generally
accepted that inflammation of the airways underlies the pathogenesis of asthma.
The 24 hours variation in endogenous rhythms such as bronchial responsiveness,
the autonomic central nervous system and cortisol secretion modulate the in-
flammatory processes in the airways, resulting in variation of the airway diameter
over 24 hours. In our concept of nocturnal airflow limitation in asthmatic children
we hypothesize that the severity of this basic inflammatory process may be enhan-
ced by exogenous triggers, such as exposure to allergens and non-allergic triggers,
resulting in larger circadian swings in lung function.
In Chapter 2 we describe a study in which we investigated the frequency of
nocturnal symptoms such as cough, wheeze, shortness of breath, and dyspnea on
awakening in the morning in 796 consecutive children with asthma attending our
outpatient clinic. Nocturnal symptoms were reported in 47% of the children; 6%
every night and 34% at least once a week. Only 38% of these 47% with nocturnal
symptoms reported these spontaneously. Patients with nocturnal symptoms had a
lower FEV1, perceived their asthma as more severe, and had their daytime activities
more affected than those without nocturnal symptoms. FEV1 seemed to be a poor
predictor for nocturnal symptoms. These results confirm that nocturnal symptoms
of asthma reflect a more severe disease state. Furthermore it shows that doctors
should specifically ask about nocturnal symptoms as they are not spontaneously
mentioned. This offers the possibility to introduce appropriate treatment.
In Chapter 3 we have tried to answer the question whether house dust mite (HDM)
exposure levels in living and bedrooms of 25 asthmatic children are higher than in
those of age and sex matched healthy children, living in the same area. HDM
allergen (HDMA) concentrations were not significantly different between the two
groups, although a higher cleaning frequency, and more smooth floor coverings
were reported in the asthmatic group. We observed that low HDMA concentrations
were a general finding in Dutch dwellings in the present generation of children.
Smooth floor coverings contained less fine dust and lower concentrations of
HDMA than carpeted floors. The large interindividual variation in HDMA
concentrations in the different houses suggests an individual approach with regard
to environmental measures.
109Chapter 4 contains a study in which we investigated in 55 asthmatic children with
a mono-allergy to HDM the contribution of exogenous triggers, such as
environmental tobacco smoke, the presence of pets, and levels of HDMA in living
rooms, bedrooms, mattresses (n=25) and classrooms to an increased circadian PEF
amplitude (PEF value every 4 hours during 24 hours expressed as highest minus
lowest value expressed as a percentage of the day’s mean value). All children were
well controlled with daily ICS. To investigate the influence of these triggers on the
circadian PEF amplitude, ICS were withdrawn for 6 days. We found that exposure
to environmental tobacco smoke, the presence of pets and high exposure to HDMA
concentrations in bedding contributed independently to a higher PEF amplitude
after withdrawal of ICS. Highest HDMA exposure sources were mattresses and
carpets on a smooth floor.
In Chapter 5 a study is presented assessing whether a seasonal difference in
HDMA exposure contributed to an increase in circadian PEF amplitude in 25
asthmatic children with a mono-allergy to HDM. In all children HDMA were
collected in living rooms, bedrooms and from the surface of mattresses by vacuum
cleaning. In both spring and autumn, PEF amplitude was measured before and 6
days after withdrawal of ICS. This cross- sectional study showed that a higher PEF
amplitude was not significantly associated with higher HDMA exposure in
mattresses. However, the change in HDMA exposure over seasons (autumn value
minus spring value) contributed significantly to the change in PEF amplitude after
withdrawal of ICS.
The results of both studies in chapter 4 and 5 strongly suggest that superimposed
exogenous triggers enhance the magnitude of the circadian variation in airway
diameter next to endogenous modulation.
Chapter 6 is a letter to the editor in answer to a study of De Lovinfosse et al.
published in Allergy 1994; 49: 64-66 in which the authors showed a correlation
between HDM specific IgE and HDMA exposure levels and suggested that mite
specific IgE could be used as a surrogate for mite exposure. In 25 asthmatic
children with an isolated allergy to HDM we tried to correlate the same variables
(serum mite specific IgE and HDMA levels collected from mattresses). We did not
observe a correlation and we could not confirm their statement. This seems logical
since the immunological ability of an individual to react to a certain amount of
HDM is a probably more relevant factor that may influence IgE production.
In Chapter 7 we present results of a study in forty asthmatic children who were
already on daily ICS and randomly treated for 16 weeks with the long-acting ß2-
agonist salmeterol or placebo. The effects on FEV1 and bronchial responsiveness
both during the day and overnight were investigated. Furthermore, we assessed
whether cessation of salmeterol after 4 months led to a rebound increase in
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bronchial responsiveness. We observed in the salmeterol group a sustained higher
FEV1 and an improved circadian variation in airway diameter than in the placebo
group from 1 to 16 weeks of treatment. Overall mean PC20 methacholine from 1 to
16 weeks of treatment was not significantly different between the salmeterol and
placebo groups. This lack of improvement in PC20 in the salmeterol group could
not be explained by a ceiling effect since all children had moderate to severe
bronchial responsiveness and all children had enough room for improvement.
Cessation of salmeterol after 16 weeks of treatment did not lead to a rebound
increase in bronchial responsiveness.
In Chapter 8 we present another aspect of this same study and investigated whether
addition of salmeterol to treatment with ICS leads to a beneficial effect on inflam-
matory variables in peripheral blood during the day as well as overnight. Blood
was collected from the same children in the same study as mentioned in chapter 7.
Besides this question, we investigated whether a difference in these inflammatory
variables existed between the asthmatic children and a healthy control group, and
whether these differences in inflammatory parameters are associated with lung
function parameters. We observed that children, despite their treatment with ICS,
do have ongoing eosinphilic activation at day and night and lymphocytic activation
in daytime. Eosinophilic activation was related to the variability in airway
diameter, whereas lymphocytic activation was associated with the level of FEV1.
Despite clinical improvement with salmeterol treatment, we could not find any
improvement in inflammatory parameters in daytime, even though there was room
for improvement given the observed differences in inflammatory parameters
between healthy and asthmatic children treated with ICS.
Final conclusions and recommendations
Nocturnal symptoms are still frequently present in a population of children with
asthma who are under control in an asthma outpatient clinic. FEV1 seems to be a
poor predictor for nocturnal symptoms, and doctors should specifically ask for
these symptoms because this offers the opportunity to take adequate measures.
Since the end of this epidemiological study on the frequency of nocturnal
symptoms newer therapeutic options such as mattress encasings and drugs
especially beneficial for nocturnal symptoms became available. It seems worthwhile
to repeat such a study in the near future because this may give insight in possible
shifts in nocturnal symptoms in this population.
The studies in this thesis add new insights to the concept on the pathophysiology of
nocturnal airflow limitation in asthmatic children. Exogenous factors such as
environmental tobacco smoke, the presence of pets, and high HDMA levels all
independently contribute to the circadian PEF amplitude in allergic asthmatic
111children. Parents should not only be stressed to stop smoking during pregnancy, but
also any time thereafter to improve the stability and the prognosis of their childs
asthma. Another important message is that pets contribute to an enhanced circadian
PEF variability even in asthmatic children who do not express allergies to these
pets. It seems appropriate to assess whether withdrawal of these pets improves
asthma stability. HDM in mattresses provide the most important contribution to the
circadian variation in airway diameter compared to other sources of HDM
exposure.
Children with asthma are exposed to comparable HDM levels as healthy children.
More smooth floor coverings were observed in asthmatic children probably as a
result of earlier given advises. Smooth floors contained less HDM than carpeted
floors, indicating that environmental advises should include the elimination of
carpeted floors.
The concept of the circadian variation in airway diameter in asthmatic children that
superimposed endogenous circadian rhythms such as for bronchial responsiveness,
the autonomic central nervous system and cortisol secretion play an important and
intricate role in the circadian modulation of the inflammatory process by changing
numbers of cells, their release of mediators and/or the susceptibility of airway
smooth muscle and vasculature needs further support. It is an attractive concept to
hypothesize that endogenous secretion of cortisol conducts this inflammatory
process. Low cortisol levels at night, or a more general lower cortisol secretion in
asthmatic children with nocturnal symptoms oppose possible protection against
inflammatory processes. This needs further investigation.
Long-acting ß2-adrenergic bronchodilators are a good tool in the treatment of
nocturnal airflow limitation. Even in stable asthmatic children who were already
treated with ICS we observed a sustained bronchodilating effect of salmeterol and a
reduction in circadian airflow limitation. We did not find a protective effect on
bronchial responsiveness despite that all children had enough room to improve. We
did not observe a rebound effect on bronchial responsiveness after cessation of
salmeterol. Little evidence remains that salmeterol has anti-inflammatory properties.
Future studies on treatment of nocturnal symptoms in allergic asthmatic children
should focus on optimal treatment regimes. Mattress encasings and long-acting ß2-
adrenergic drugs such as salmeterol seem to be successful interventions together
with anti-inflammatory treatment with ICS. However, smoking cessation and pet
avoidance should be advised in every child with unstable asthma.
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Nachtelijke luchtwegklachten worden vaak gemeld bij kinderen met astma. Over
het algemeen wordt dit toegeschreven aan een toegenomen vernauwing en bronchi-
ale hyperreaktiviteit (gevoeligheid/prikkelbaarheid van de luchtwegen) gedurende
de nacht. Zowel bij gezonde kinderen als bij kinderen met astma is een circadiane
(24 uurs) variatie in luchtwegdiameter beschreven. Deze 24 uurs variatie in
luchtwegdiameter is bij gezonde kinderen klein. Bij mensen met astma kan deze
variatie uitgesproken zijn, met name tijdens een instabiele periode van de ziekte.
De beste longfunktiewaarden worden overdag gemeten, terwijl de slechtste waarden
over het algemeen ’s nachts gemeten worden. Dit heeft tot gevolg dat kinderen met
astma, en hun ouders, ’s nachts wakker worden met als gevolg slechtere
schoolprestaties en verstoring van het gezinsleven.
Nachtelijke klachten ten gevolge van astma zijn al lange tijd onderkend en beschre-
ven. De eerste meldingen van nachtelijk toegenomen luchtwegvernauwing stammen
uit de vierde eeuw na Chr. In de veertiger en vijftiger jaren van deze eeuw begon
de wetenschappelijke interesse naar de nachtelijk toegenomen luchtwegvernauwing
te ontstaan. De Groninger onderzoeksgroep leverde een bijdrage hieraan. Tot nu toe
heeft het wetenschappelijk onderzoek zich met name bezig gehouden met endogene
ritmes, zoals de bijdrage van de variatie van het autonome zenuwstelsel, variaties
in cortisol produktie, of de associatie met variatie in inflammatoire (ontstekings)
parameters en de nachtelijke daling in longfunktie. Hoewel delen van de puzzel
opgehelderd zijn, zijn andere gedeelten nog volstrekt onbekend. Tijdens een eerdere
studie bij allergische kinderen met astma vonden we dat de nachtelijke
luchtwegvernauwing die thuis was gemeten, significant verminderde tijdens een
kort verblijf in het ziekenhuis. Hieruit ontstond de hypothese dat naast endogene
factoren, ook exogene factoren (omgevingsfactoren) zoals allergenen en
sigarettenrook een bijdrage leveren aan de circadiane variatie in luchtwegdiameter.
Dit proefschrift tracht meer inzicht te geven in de epidemiologie van nachtelijke
luchtwegklachten bij astmatische kinderen die regelmatig een specialistische
polikliniek voor astma bezoeken. Tevens wordt in dit proefschrift getracht de vraag
te beantwoorden of omgevingsfactoren van invloed zijn op de mate van nachtelijke
luchtwegvernauwing bij allergische kinderen met astma. Zoals gezegd wordt
verondersteld dat het inflammatoire proces in de longen ’s nachts toeneemt.
Omgevingsfactoren, zoals allergenen, zouden dit inflammatoire proces kunnen
activeren.
Diverse onderzoeken suggereren dat het inflammatoire proces gedurende de nacht
actiever is bij mensen met nachtelijk toegenomen luchtwegvernauwing. Deze
studies laten een toename van ontstekingscellen en mediatoren in het bloed en in
de urine zien bij patienten met nachtelijke luchtweg vernauwing, in tegenstelling tot
patiënten die dit niet hebben (1-4). Meer directe bewijzen hiervoor zijn de
toegenomen hoeveelheid ontstekingscellen en activatie van ’markers’ in broncho-
alvelolaire spoelvloeistof (longspoeling) gedurende de nacht (5,6). Anti-inflamma-
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onderdrukken de mate van inflammatie en beperken de circadiane variatie in de
piekstroom (PEF) (7,8). Aangetoond is dat langwerkende luchtwegverwijdende ß2-
agonisten bij patiënten met astma met name effectief zijn om de nachtelijke daling
in longfunktie te overbruggen (9). In de eerste studies met deze langwerkende ß2-
agonisten werd gesuggereerd dat deze medicijnen ook anti-inflammatoire
eigenschappen zouden hebben, omdat een éénmalige inhalatie zowel de vroege als
ook de late astmatische reactie na allergeen inhalatie zou voorkomen (10). Mede
hierdoor ingegeven bestudeerden wij het effect, zowel overdag als ’s nachts, van
een 16 weken durende behandeling met de langwerkende ß2-agonist salmeterol. We
onderzochten het effect op de longfunktie, op de mate van bronchiale
hyperreaktiviteit en op inflammatoire variabelen in het bloed van allergische
kinderen met astma met een onderhoudsbehandeling van ICS.
Hoofdstuk 1.1 laat een literatuuroverzicht zien van de epidemiologie van nachtelijke
klachten bij astma in verschillende groepen. Hierin worden onderliggende
modulerende mechanismen besproken die het circadiane verloop van de longfunktie
beïnvloeden. Het wordt algemeen geaccepteerd dat inflammatie het onderliggende
pathologisch mechanisme is van astma. De circadiane variatie van het endogenene
ritme zoals bronchiale hyperreaktiviteit, het autonome zenuwstelsel en de cortisol
secretie moduleren het inflammatoire proces in de luchtwegen. Dit resulteert in een
variabele luchtwegdiameter gedurende 24 uur. In ons model van nachtelijke
luchtwegvernauwing bij kinderen met astma, veronderstellen we dat de ernst van
het onderliggende inflammatoire proces verergerd wordt door uitlokkende
omgevingsfactoren zoals expositie aan allergenen en niet-allergische prikkels, resul-
terend in een grotere 24 uurs variatie van de longfunktie.
In Hoofdstuk 2 worden de resultaten besproken van een studie waarin we het
voorkomen van nachtelijke klachten zoals hoesten, piepen, kortademigheid en
ochtendbenauwdheid onderzochten. In deze studie bestudeerden we de nachtelijke
klachten van 796 kinderen met astma die opeenvolgend onze polikliniek voor
kinderlongziekten bezochten. Nachtelijke klachten werden door 47% van de
kinderen gemeld; 6,3% had elke nacht klachten en 34% had tenminste 1x per week
klachten passend bij nachtelijke luchtwegvernauwing. Slechts 38% van de 47% die
nachtelijke klachten melden, meldde dit spontaan aan de arts. Patiënten met nachte-
lijke klachten hadden een lagere FEV1, ervaren hun astma ernstiger en hun
dagelijkse activiteiten werden meer beïnvloed door astma dan bij de groep kinderen
zonder nachtelijke klachten van astma. Een éénmalig op de polikliniek geblazen
FEV1 blijkt een slechte voorspellende waarde te hebben voor nachtelijke klachten.
Deze resultaten bevestigen dat nachtelijke klachten tengevolge van astma een
ernstiger vorm van astma weerspiegelen. Bovendien moeten artsen specifiek naar
nachtelijke klachten vragen omdat deze niet spontaan gemeld wordt door de
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patiënt. Nachtelijke klachten bieden een opening om adequate therapie te
introduceren.
In Hoofdstuk 3 hebben we getracht de vraag te beantwoorden of het nivo van
blootstelling aan huisstofmijt (HSM) in woon- en slaapkamers van 25 kinderen met
astma hoger is dan bij gezonde kinderen in dezelfde leeftijd en van het zelfde
geslacht, die in dezelfde omgeving wonen. Huisstofmijtallergeen (HSMA)
concentraties waren niet significant verschillend tussen de 2 groepen, hoewel er een
hogere schoonmaakfrequentie gevonden werd en er meer gladde vloerbedekking lag
in de huizen van de groep kinderen met astma. We vonden dat bij deze
Nederlandse schoolgaande kinderen in Nederland over het algemeen lagere HSMA
concentratie dan in andere landen gemeld wordt. Gladde vloerbedekking bevatte
significant minder stof en een lagere HSMA concentratie in vergelijking met vaste
vloerbedekking. De grote inter-individuele verschillen in HSMA concentratie in de
verschillende huizen rechtvaardigd het geven van individuele saneringsadviezen.
Hoofdstuk 4 beschrijft de resultaten van een studie waarbij we bij 55 kinderen met
astma en een mono-allergie voor HSM de bijdrage van omgevingsfactoren, zoals
het blootstellen aan sigarettenrook, de aanwezigheid van huisdieren en van de
blootstelling aan HSMA in woon- en slaapkamers, in matrassen (n = 25) en in het
schoollokaal, bestudeerden aan een toegenomen schommeling in piekstroom (PEF)
amplitude (gedurende 24 uur elke 4 uur een PEF waarde blazen, amplitude
berekend als hoogste min laagste waarde uitgedrukt als percentage van het
daggemiddelde). Alle kinderen werden adequaat behandeld met dagelijks onder-
houdsmedicatie bestaande uit ICS. Om de invloed van deze prikkels op de
circadiane variatie in PEF amplitude te onderzoeken werden de ICS gedurende 6
dagen voor de metingen gestopt. We vonden dat het blootstellen aan sigarettenrook,
de aanwezigheid van huisdieren en een hoge HSMA concentratie in het matras,
ieder voor zich bijdroegen aan een toegenomen PEF amplitude. De hoogste HSMA
concentratie werd gevonden in matrassen én op gladde vloeren waarop een los
tapijt ligt.
In Hoofdstuk 5 worden de resultaten gepresenteerd van een studie waarbij we
onderzochten of het seizoensverschil in HSMA expositie bijdraagt aan een toename
van de circadiane schommeling van de PEF amplitude bij 25 kinderen met astma
die een mono-allergie voor HSM hebben. Bij alle kinderen werden d.m.v. het
verzamelen van stofmonsters, de hoeveelheid HSMA bepaald in de woon- en
slaapkamer en op het matras. In zowel de lente als in de herfst werden PEF ampli-
tudes gemeten tijdens het gebruik van ICS en op de zesde dag na het staken van
ICS. Deze cross-sectionele studie laat zien dat een hogere HSMA expositie in het
matras niet geassocieerd is met een hogere PEF amplitude. De seizoensverandering
in HSMA expositie (herfstwaarde minus lentewaarde), evenwel, draagt significant
117bij aan de verandering in PEF amplitude na het staken van ICS.
De resultaten van de studies beschreven in hoofdstuk 4 en 5 ondersteunen de
veronderstelling dat blootstelling aan exogene factoren, naast endogene factoren, de
grootte van de circadiane variatie in de luchtwegdiameter beïnvloeden.
Hoofdstuk 6 is een letter to the editor als reactie op een studie van De Lovinfosse
et al. gepubliceerd in Allergy 1994; 49: 64-66 waarin de auteurs een correlatie
lieten zien tussen HSM specifiek IgE en de HSMA concentratie en suggereerden
dat HSM specifiek IgE gebruikt kan worden als een alternatief voor HSMA
expositie. Bij 25 kinderen met astma en een geïsoleerde allergie voor HSM hebben
we getracht om dezelfde variabelen te correleren (serum HSM specifiek IgE en de
HSMA concentratie op matrassen). Wij vonden geen correlatie tussen beide
variabelen en konden de veronderstelling van De Lovinfosse et al. niet bevestigen.
Dit lijkt ons inziens aannemelijk omdat de individuele immunologische
mogelijkheid om te reageren op een bepaalde hoeveelheid HSM waarschijnlijk een
meer relevante faktor is die de IgE produktie beïnvloedt.
In Hoofdstuk 7 presenteren wij de resultaten van een 16 weken durende studie waar
40 kinderen met astma die al langere tijd behandeld werden met een ICS en voor
deze studie at random behandeld werden met het langwerkende luchtwegver-
wijdende salmeterol of met placebo. De effecten op FEV1 en op bronchiale
hyperreaktiviteit, beide zowel overdag als ’s nachts gemeten, werden onderzocht.
Bovendien hebben we gekeken of het staken van salmeterol na 4 maanden gebruik,
leide tot een toename in bronchiale hyperreaktiviteit als een ’rebound’ effect. We
vonden in de salmeterol groep een aanhoudend hogere FEV1 en een verbetering in
circadiane variatie van de luchtwegdiameter in vergelijking met de placebo groep
gedurende1-1 6weken. De mate van bronchiale hyperreaktiviteit gedurende 1-16
weken was niet significant verschillend tussen beide groepen. Het achterwege
blijven van verbetering van de bronchiale hyperreactiviteit kon niet verklaard
worden door een ’plafond’ effect omdat alle kinderen een matige tot ernstige
bronchiale hyperreaktiviteit hadden en er voldoende ruimte voor verbetering moge-
lijk was. Staken van salmeterol na 16 weken dagelijks gebruik, gaf geen rebound
verslechtering van de bronchiale hyperreaktiviteit.
In Hoofdstuk 8 presenteren we een ander onderdeel van deze zelfde studie zoals
beschreven in hoofdstuk 7. We onderzochten of toevoeging van salmeterol aan de
behandeling met ICS leidt tot een verbetering van inflammatoire variabelen in
bloed, zowel overdag als ’s nachts. Behalve deze vraag hebben we gekeken of deze
parameters bij allergische kinderen met astma, die dagelijks ICS gebruiken, ver-
schillen van gezonde kinderen. We vonden dat kinderen met astma, ondanks
behandeling met ICS, nog steeds een verhoogde activatie van eosinofiele cellen
hebben, zowel overdag als ’s nachts, en een toegenomen activatie van de lymfocy-
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ten overdag. Eosinofiele activatie is gecorreleerd aan de variatie in luchtwegdia-
meter, terwijl de lymfocyten activatie geassocieerd is met de hoogte van de FEV1.
Ondanks klinische verbetering door de behandeling met salmeterol konden we geen
verbetering van inflammatoire parameters overdag aantonen, terwijl er genoeg
ruimte was voor verbetering gezien de waargenomen verschillen in inflammatoire
parameters tussen de gezonde kinderen en de kinderen met astma.
Slotconclusies en aanbevelingen
Nachtelijke klachten komen veelvuldig voor in een populatie kinderen met astma
die onder controle staan op een specialistische polikliniek voor astma. FEV1 heeft
een slecht voorspellende waarde voor nachtelijke klachten bij astma. Artsen moeten
specifiek vragen naar nachtelijke symptomen omdat dit een ingang biedt om
adequate behandeling te nemen. Na het afronden van deze epidemiologische studie
kwamen er nieuwe therapeutische mogelijkheden zoals matrashoezen en medicijnen
speciaal voor nachtelijke klachten. Het lijkt zeer de moeite waard om deze studie in
de nabije toekomst te herhalen omdat verder onderzoek meer inzicht zal geven in
een mogelijk veranderd patroon van nachtelijke klachten binnen deze populatie.
De studies in dit proefschrift geven nieuwe inzichten in de gedachtengang rond de
pathofysiologie van nachtelijke luchtwegvernauwing bij kinderen met astma.
Exogene factoren zoals blootstelling aan sigarettenrook, de aanwezigheid van huis-
dieren en een hoge blootstelling aan HSMA in het matras, dragen alle individueel
bij aan de circadiane PEF amplitude van allergische astmatische kinderen. HSMA
uit matrassen draagt het meeste bij aan de circadiane variatie in luchtwegdiameter
in vergelijking met andere HSMA bronnen. Deze studie laat zien dat ouders niet
alleen moeten stoppen met roken tijdens de zwangerschap, maar ook daarna niet
meer moeten roken om de stabiliteit en de prognose van het astma van hun kind te
verbeteren. Een andere belangrijke conclusie is dat huisdieren bijdragen aan een
toename in circadiane PEF variatie, zelfs bij kinderen met astma die geen aantoon-
bare allergie hebben voor deze dieren. Het is aan te raden om een ander onder-
komen voor huisdieren te zoeken om de stabiliteit van het astma te bevorderen.
Kinderen met astma worden blootgesteld aan vergelijkbare HSMA hoeveelheden
als gezonde kinderen. Kinderen met astma hebben vaker gladde vloerbedekking in
de woon- en slaapkamer, waarschijnlijk als een gevolg van eerder gegeven
informatie omtrent het aanpassen van de woonomgeving. Gladde vloeren hebben
een lagere HSM expositie als vaste vloerbedekking. Dit betekent dat bij het geven
van adviezen aandacht besteed moet worden aan het verwijderen van vaste
vloerbedekking.
Het concept dat gesuperponeerde endogene 24 uurs ritmes, zoals de bronchiale
hyperreaktiviteit, van het autonome zenuwstelsel en van de cortisol secretie een
belangrijke rol spelen bij de 24 uurs veranderingen van het ontstekingsproces in de
119luchtwegen behoeft verdere onderbouwing.
Het is een aantrekkelijke hypothese om te veronderstellen dat de endogene cortisol
secretie dit ontstekingsproces regisseert. Lage cortisolspiegels gedurende de nacht
of een in het algemeen lagere cortisolsecretie bij kinderen met astma en nachtelijke
symptomen versterken mogelijk het inflammatoire proces. Dit dient nader
onderzocht te worden.
Langwerkende ß2-adrenerge luchtwegverwijders zijn een goed alternatief in de
behandeling van nachtelijke luchtwegbeperking. We vonden een aanhoudend
luchtwegverwijdend effect en een vermindering van de 24 uurs variatie van de
luchtwegdiameter bij kinderen met astma die naast hun ICS met salmeterol
behandeld werden. We konden geen beschermend effect op de bronchiale hyperre-
aktiviteit aantonen, hoewel alle kinderen de mogelijkheid hadden om te verbeteren.
We vonden geen rebound effect in bronchiale hyperreaktiviteit na het staken van
salmeterol. Dit alles geeft weinig aanleiding om te veronderstellen dat salmeterol
anti-inflammatoire eigenschappen heeft.
Nadere studies naar de behandeling van nachtelijke klachten van allergisch astmati-
sche kinderen moeten gericht zijn op een optimaal therapeutisch regime. Matras-
hoezen en langwerkende luchtwegverwijders zoals salmeterol lijken succesvolle
interventies, wanneer ze gecombineerd worden met anti-inflammatoire therapie
zoals ICS. Desalniettemin zou stoppen met roken en het afschaffen van huisdieren
ten zeerste geadviseerd moeten worden aan elk gezin met een kind met instabiel
astma.
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Gerda Rosman-MeijerI Nachtelijke luchtwegklachten bij kinderen zoals hoesten, piepen, kortademig-
heid en benauwdheid komen frequent voor, men moet er echter wel naar
vragen.
II Gezinnen met kinderen met astma hebben vaker gladde vloerbedekking en
daardoor een lagere huisstofmijtallergeen expositie dan gezinnen met
gezonde kinderen.
III Blootstelling aan sigarettenrook, huisstofmijt en huisdieren draagt bij aan een
toegenomen piekstroom amplitude bij kinderen met astma.
IV De seizoensschommeling in huisstofmijtallergeen expositie draagt bij aan
een seizoensschommeling van het circadiane beloop van de longfunktie.
V Salmeterol verbetert de nachtelijke FEV1 ook op lange termijn, doch niet de
nachtelijke bronchiale hyperreaktiviteit.
VI Kinderen met astma gebruiken minder vaak hun dagelijks anti-inflammatoire
medicatie dan is voorgeschreven. Luchtwegverwijders worden vaker dage-
lijks gebruikt dan is voorgeschreven.
VII Een donzen kussen is des duivels oorkussen.
VIII Een passief roker met astma is de sigaar.
IX Zoals hun ouders longen, piepen die van de jongen.
X Adviezen rond roken in relatie tot astma zijn maar al te vaak vrijblijvend.
XI Het routinematig aanvragen van een uitgebreide allergietest bij een zuigeling
met luchtwegproblemen is niet zinvol.
XII ’t kon minder en goed te pas geven dezelfde anamnestische informatie.